{"title":"Longevity Services","description":"\u003cp\u003eDiscover your biological age and optimize your healthspan with EMIS+ longevity screening services in Singapore. Our comprehensive health assessments include executive brain-span audits, metabolic engine tracking, structural longevity scans (DEXA), cellular oxygenation audits (VO2 Max), intracellular NAD+ assessments, gut microbiome analysis, hormonal balance panels, and advanced cellular senescence testing. From DNA-based cancer risk screening to comprehensive age-related biomarker analysis, our longevity protocols are designed to help you understand, monitor, and improve your health at the cellular level.\u003c\/p\u003e","products":[{"product_id":"metabolic-recomposition-protocol-mrp","title":"Metabolic Recomposition Protocol (MRP)","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f6ff;border-left:4px solid #0057a8;padding:12px 16px;margin-bottom:16px;font-family:Arial,sans-serif;font-size:14px;line-height:1.5;\"\u003e\n\u003cstrong\u003eMetabolic Recomposition Protocol (MRP) — Clinical Summary\u003c\/strong\u003e\u003cbr\u003e\nA structured 12-week medically supervised weight management programme combining GLP-1\/GIP receptor agonist pharmacotherapy, continuous glucose monitoring (CGM), dietary behaviour tracking, and weekly clinical review. Designed for adults with overweight or obesity (BMI ≥27 with metabolic comorbidity, or BMI ≥30) seeking sustained body composition improvement — specifically fat mass reduction while preserving lean muscle mass. Delivered by EMIS's longevity medicine team in Singapore.\n\u003c\/div\u003e\n\n\u003ch2 style=\"font-size:16px;color:#1a1a1a;margin-top:0;\"\u003eProgramme Components\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:13px;font-family:Arial,sans-serif;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;width:40%;\"\u003eComponent\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eDuration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e12 weeks (structured programme with defined milestones)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePharmacotherapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003eGLP-1\/GIP receptor agonist medication management — includes prescribing review, dose titration, and monitoring by licensed clinician\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eMetabolic Monitoring\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003eContinuous Glucose Monitor (CGM) — real-time interstitial glucose tracking for dietary response analysis and metabolic pattern identification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eDietary Tracking\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003ePersonal food journaling application with macronutrient logging and CGM integration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eApp Access\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003eLifetime access to the programme app — dietary log, progress tracking, educational content\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eClinical Reviews\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003eWeekly check-ins with the EMIS longevity medicine team — clinical progress review, dose adjustment, and behavioural coaching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTarget Outcome\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e10–15% body fat reduction over 12 weeks; lean muscle mass preservation via protein-optimised dietary protocol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eProgramme Delivery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;border-bottom:1px solid #e0e0e0;\"\u003eSingapore-based; in-person assessment + remote weekly reviews; medication dispensed at licensed pharmacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:7px 10px;\"\u003e\u003cstrong\u003eRegulatory Framework\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:7px 10px;\"\u003eGLP-1\/GIP medications prescribed under Singapore Medical Council guidelines; HSA-licensed pharmacy dispensing; CGM devices HSA-registered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"font-size:16px;color:#1a1a1a;margin-top:20px;\"\u003eClinical Eligibility Criteria\u003c\/h2\u003e\n\u003cul style=\"font-size:13px;font-family:Arial,sans-serif;line-height:1.6;margin:0 0 16px 0;padding-left:18px;\"\u003e\n\u003cli\u003eBMI ≥30 kg\/m² (obesity), or BMI ≥27 kg\/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea)\u003c\/li\u003e\n\u003cli\u003eInadequate response to lifestyle intervention alone (diet and exercise) for ≥3 months\u003c\/li\u003e\n\u003cli\u003eNo contraindications to GLP-1\/GIP receptor agonist therapy (personal or family history of medullary thyroid carcinoma, MEN2, or pancreatitis)\u003c\/li\u003e\n\u003cli\u003eCommitted to 12-week programme duration with weekly review attendance\u003c\/li\u003e\n\u003cli\u003eAged 21–70 years; Singapore resident with access to programme pharmacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 style=\"font-size:16px;color:#1a1a1a;margin-top:20px;\"\u003eCommunity Consensus: Clinical Q\u0026amp;A\u003c\/h2\u003e\n\n\u003cp style=\"font-size:13px;font-family:Arial,sans-serif;line-height:1.6;\"\u003e\u003cstrong\u003eQ: How do GLP-1\/GIP receptor agonists support body composition recomposition?\u003c\/strong\u003e\u003cbr\u003e\nGLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists reduce appetite via central hypothalamic satiety signalling and slow gastric emptying, resulting in sustained caloric deficit without the compensatory hunger typically associated with calorie restriction alone. When combined with adequate dietary protein (≥1.6g\/kg\/day) and resistance activity, the caloric deficit preferentially reduces adipose tissue while preserving lean muscle mass — the physiological basis for \"recomposition\" rather than simple weight loss. Clinical trials (SURMOUNT-1, STEP-1) demonstrate 15–22% total body weight reduction with these agents over 68–72 weeks.\u003c\/p\u003e\n\n\u003cp style=\"font-size:13px;font-family:Arial,sans-serif;line-height:1.6;\"\u003e\u003cstrong\u003eQ: What does the continuous glucose monitor (CGM) add to a weight management programme?\u003c\/strong\u003e\u003cbr\u003e\nCGM provides real-time interstitial glucose data (updated every 1–5 minutes) that reveals individual postprandial glucose responses to specific foods, meal timing, and exercise. This allows personalisation of macronutrient composition and meal structure beyond generic dietary advice. Individuals with insulin resistance or impaired glucose tolerance — common in the overweight\/obese population — may have markedly different glycaemic responses to the same food compared to metabolically healthy individuals. CGM-guided dietary modification has been shown to improve glycaemic variability and dietary adherence in weight management programmes.\u003c\/p\u003e\n\n\u003cp style=\"font-size:13px;font-family:Arial,sans-serif;line-height:1.6;\"\u003e\u003cstrong\u003eQ: Is GLP-1 medication included in the $3,299 programme fee?\u003c\/strong\u003e\u003cbr\u003e\nThe programme fee covers clinical assessment, CGM device, app access, and all 12 weekly reviews. GLP-1\/GIP medication costs are separate and subject to individual prescribing — medication cost varies by agent selected, dose titrated to, and response. Common agents used in Singapore include semaglutide (Ozempic®\/Wegovy®) and tirzepatide (Mounjaro®), which are prescribed under the Singapore Medical Council's Prescribing Framework and dispensed at HSA-licensed pharmacies. EMIS's clinical team will advise on medication cost estimates at initial consultation.\u003c\/p\u003e\n\n\u003cp style=\"font-size:13px;font-family:Arial,sans-serif;line-height:1.6;\"\u003e\u003cstrong\u003eQ: What is the evidence base for 10–15% body fat reduction in 12 weeks?\u003c\/strong\u003e\u003cbr\u003e\nThe 10–15% body fat reduction target is based on combined outcomes from GLP-1\/GIP pharmacotherapy trials and structured behaviour change programmes. The SURMOUNT-1 trial (tirzepatide, 72 weeks) demonstrated 20.9% mean body weight reduction; earlier phase data show approximately 1–1.5% body weight reduction per week during active titration. A 12-week programme targeting 10–15% body fat reduction is clinically plausible with medication compliance, CGM-guided dietary adherence, and adequate protein intake. Individual results vary based on baseline metabolic status, medication response, and adherence.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Metabolic Recomposition Protocol (MRP) used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Metabolic Recomposition Protocol (MRP) by EMIS + is a medical supply item used in clinical and home care settings. It is designed for use by healthcare professionals and trained home care users. Always follow the manufacturer's instructions and relevant clinical guidelines when using medical devices. For guidance on proper use, consult your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Metabolic Recomposition Protocol (MRP) suitable for home use?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Some EMIS + products are designed for both clinical and home use, while others are intended for use by trained healthcare professionals only. Check the product labelling and consult your doctor, nurse, or pharmacist to confirm whether Metabolic Recomposition Protocol (MRP) is appropriate for home use in your situation. EMIS+ nurses are available to advise — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Does Metabolic Recomposition Protocol (MRP) require a prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"In Singapore, many medical supplies and devices do not require a prescription for purchase. However, certain controlled medical devices may require professional authorisation. EMIS+ sells products in compliance with HSA (Health Sciences Authority) Singapore regulations. Contact us at emis.asia if you need clarification on a specific product.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Metabolic Recomposition Protocol (MRP) in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Metabolic Recomposition Protocol (MRP) is available from EMIS+ at emis.asia, Singapore's trusted nurse-led medical supply store. We serve hospitals, nursing homes, clinics, and home care users across the island with fast delivery and competitive pricing. Bulk and institutional orders are welcome.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525720539214,"sku":null,"price":3299.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"linage2-comprehensive-health-age-screen","title":"LinAge2 Comprehensive Health Age Screen","description":"\u003cdiv id=\"ai-summary\"\u003e\u003cp\u003e\u003cstrong\u003eLinAge2 Comprehensive Health Age Screen\u003c\/strong\u003e — EMIS+, Singapore. SGD 980. Multi-dimensional biological age assessment profiling six concurrent ageing systems to generate an Integrated Health Age Score and system-by-system ageing rate analysis: (1) Epigenetic biological age — DNA methylation clocks (GrimAge, PhenoAge); (2) Cardiovascular health age — ApoB, Lp(a), hsCRP, homocysteine, arterial stiffness indices; (3) Metabolic health age — HbA1c, fasting insulin, HOMA-IR, glucose variability, body composition; (4) Hormonal age — testosterone (LC-MS\/MS), oestradiol, DHEA-S, IGF-1, cortisol, TSH, free T3\/T4; (5) Immune age — immunosenescence markers, SASP cytokine panel (IL-6, TNF-alpha, GDF-15), NAD+ availability (HPLC-MS); (6) Neurological health age — cognitive function battery (processing speed, executive function, memory indices), BDNF, neurofilament light chain (NfL), GFAP. Output: weighted Integrated Health Age Score vs Singapore-population norms, domain Z-score ranking (identifies fastest-ageing systems), personalised multi-system longevity protocol targeting highest-deviation domains. Laboratory accreditation: ISO 15189:2022. Singapore MOH regulated. Available at emis.asia\/products\/linage2-comprehensive-health-age-screen.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2\u003eLinAge2 Comprehensive Health Age Screen: Domain Panel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eBiological Age Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eBiomarkers \/ Method\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eEpigenetic Biological Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eGrimAge and PhenoAge DNA methylation clocks; Illumina EPIC array or targeted bisulfite sequencing; CpG methylation at validated age-predictive loci\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eGrimAge predicts time-to-death with greater accuracy than any single clinical biomarker; 5-year acceleration = 16–21% all-cause mortality increase; responds to modifiable lifestyle interventions (Lu et al., Nature Aging 2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eCardiovascular Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eApoB (IFCC standardised), Lp(a), hsCRP, homocysteine, LDL-C, HDL-C, triglycerides, non-HDL-C, NT-proBNP, arterial stiffness index\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eApoB superior to LDL-C per ACC\/AHA 2023; Lp(a) \u0026gt;50 mg\/dL: 3× ASCVD risk; NT-proBNP \u0026gt;125 pg\/mL flags subclinical cardiac dysfunction; cardiovascular age acceleration detects ASCVD risk decade before clinical events\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eMetabolic Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eHbA1c, fasting glucose, fasting insulin, HOMA-IR, uric acid, liver enzymes (ALT\/AST\/GGT), body composition (bioelectrical impedance or DEXA reference), metabolic flexibility indices\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eHOMA-IR \u0026gt;2.5 indicates insulin resistance before HbA1c elevation; metabolic age acceleration is the strongest modifiable driver of overall biological age; 50% of Singapore adults show metabolic dysfunction before clinical diabetes diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eHormonal Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal testosterone (LC-MS\/MS), free testosterone (calculated), SHBG, oestradiol (E2), progesterone, DHEA-S, IGF-1, cortisol AM, TSH (3rd generation), free T3, free T4\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTestosterone declines 1–2% per year after age 30; DHEA-S declines 80% from age 25 to 70; IGF-1 below 130 ng\/mL in 40-year-olds predicts accelerated tissue ageing; hormonal age acceleration responds to targeted lifestyle and medical intervention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eImmune Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eImmunosenescence markers (CD28-\/CD57+ T-cell subset ratio), SASP cytokines (IL-6, TNF-alpha, GDF-15, IL-8, MMP-3), p16INK4a mRNA expression, NAD+ (HPLC-tandem MS), CBC with lymphocyte differential\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eCD28-\/CD57+ expansion indicates exhausted T-cell immunosenescence; SASP cytokine burden correlates with all-cause mortality independently of other biomarkers; NAD+ depletion impairs both adaptive immunity and DNA repair capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNeurological Health Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eCognitive function battery (processing speed, working memory, executive function, verbal fluency); BDNF (brain-derived neurotrophic factor); neurofilament light chain (NfL plasma); GFAP (glial fibrillary acidic protein); neuroinflammation markers (IL-6 CNS compartment correlation)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ePlasma NfL rises 10–20 years before symptomatic neurodegeneration (Alzheimer's, Parkinson's); GFAP elevation predicts amyloid pathology with 80% sensitivity; BDNF below 20 ng\/mL correlates with cognitive decline rate and depression severity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eIntegrated Health Age Score\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eWeighted composite of all six domain Z-scores vs Singapore-population age-sex normative database; domain-by-domain deviation ranking\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eSingle biological age number with ranked domain breakdown; identifies priority intervention targets by magnitude of deviation; enables 6–12-month longitudinal tracking of multi-system biological age trajectory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003ePersonalised Longevity Protocol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eNurse-curated evidence-based interventions targeted to highest-deviation domains; 45-minute consultation session; nutrition, exercise, sleep, supplementation, and medical referral recommendations\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eProtocol weighting prioritises domains showing greatest acceleration — cardiovascular age 10 years ahead receives more aggressive cardiovascular intervention than 2-year-ahead metabolic deviation; precision-targeting vs generic longevity advice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eClinical Q\u0026amp;A: LinAge2 Comprehensive Health Age Screen\u003c\/h2\u003e\n\n\u003ch3\u003eWhat neurological biomarkers does LinAge2 measure and why do they matter for early detection?\u003c\/h3\u003e\n\u003cp\u003eThe neurological domain of LinAge2 is distinguished from other longevity assessments by the inclusion of plasma biomarkers now validated as pre-symptomatic indicators of neurodegeneration. Neurofilament light chain (NfL) is a structural protein released into the bloodstream when axons are damaged or degenerate — plasma NfL begins rising measurably 10–20 years before clinical symptoms of Alzheimer's disease, Parkinson's disease, and multiple sclerosis emerge. A longitudinal study in the New England Journal of Medicine (Preische et al., 2019) demonstrated plasma NfL elevation 16 years before estimated symptom onset in genetic Alzheimer's cases. Glial fibrillary acidic protein (GFAP) is released by reactive astrocytes during neuroinflammation and amyloid pathology — plasma GFAP elevation predicts amyloid positivity on PET scanning with approximately 80% sensitivity. BDNF (brain-derived neurotrophic factor) reflects neuroplasticity capacity; below 20 ng\/mL is associated with accelerated hippocampal volume loss, treatment-resistant depression, and cognitive decline rate. These biomarkers transform neurological health age from a subjective cognitive impression into an objective, trackable biomarker trajectory — enabling pre-symptomatic intervention through aerobic exercise (the most potent BDNF elevator), sleep optimisation (critical for amyloid clearance via the glymphatic system), and metabolic control (chronic hyperinsulinaemia is the strongest modifiable driver of Alzheimer's risk in Singapore's population).\u003c\/p\u003e\n\n\u003ch3\u003eHow is immunological age measured and what does an elevated immune age indicate?\u003c\/h3\u003e\n\u003cp\u003eImmunological ageing (immunosenescence) is characterised by progressive accumulation of exhausted, senescent T-cells — specifically CD28-negative, CD57-positive effector memory T-cells that have lost co-stimulatory capacity and upregulate inhibitory receptors. The ratio of CD28-\/CD57+ T-cells to naive T-cells rises with age and with chronic viral infection burden (particularly CMV, which colonises 70–80% of Singapore adults over 40). An elevated CD28-\/CD57+ ratio indicates depleted immune repertoire diversity and reduced capacity for de novo immune responses — manifesting as greater susceptibility to novel infections, impaired vaccine response, and reduced cancer immune surveillance. The SASP cytokine panel (IL-6, TNF-alpha, GDF-15, IL-8, MMP-3) quantifies the chronic sterile inflammatory state driven by senescent cells — elevated SASP is independently associated with all-cause mortality, cardiovascular events, and cognitive decline in longitudinal data. NAD+ insufficiency impairs both the SIRT1-mediated deacetylation pathways governing inflammatory gene expression and the PARP1-dependent DNA repair capacity in lymphocytes. The immune age domain of LinAge2 thus integrates cellular immunosenescence, inflammageing burden, and metabolic immune capacity into a single actionable immune health age metric.\u003c\/p\u003e\n\n\u003ch3\u003eWhat distinguishes LinAge2 from the Advanced Cellular Blueprint and when is each preferred?\u003c\/h3\u003e\n\u003cp\u003eThe Advanced Cellular Blueprint focuses on six domains with maximum depth per domain — particularly excelling in its cellular senescence panel (p16INK4a + full SASP), mitochondrial function assessment (8-OHdG, MDA, CoQ10, citrate synthase), and telomere length measurement. LinAge2's differentiation is its neurological health age domain — plasma NfL, GFAP, BDNF, and cognitive function battery — which the Blueprint does not include. This makes LinAge2 the preferred choice for individuals with a family history of neurodegeneration, those noticing subjective cognitive changes, or longevity optimisers who prioritise brain health alongside metabolic and cardiovascular ageing. For individuals primarily concerned with cellular-level ageing mechanics (senescence, mitochondria, telomeres), the Blueprint provides deeper domain specificity. For those wanting maximum neurological coverage alongside comprehensive multi-system biological age, LinAge2 is the appropriate choice. Both tests are positioned at the same tier of longevity assessment and can be compared longitudinally at 12-month intervals.\u003c\/p\u003e\n\n\u003ch3\u003eHow is the Integrated Health Age Score calculated and weighted?\u003c\/h3\u003e\n\u003cp\u003eThe Integrated Health Age Score is a composite metric calculated from the six domain-specific Z-scores — each domain's result expressed as standard deviations above or below the age-sex-matched Singapore population mean. Domain weighting in the composite reflects both mortality prediction strength and modifiability: cardiovascular and metabolic domains carry higher composite weighting because they are (a) the strongest mortality predictors in the Singapore epidemiological context and (b) the most responsive to lifestyle intervention within a 90-day timeframe. Epigenetic age carries significant weighting as the only domain that directly measures accumulated biological ageing rather than disease risk. Neurological and immune domains receive lower composite weighting due to their longer intervention timescales, but are prioritised in the protocol if their Z-scores are highly elevated. The final Health Age Score is expressed as a biological age in years, enabling direct comparison to chronological age — a 45-year-old with a Health Age Score of 52 has an overall biological age 7 years ahead of their chronological age, with the system-by-system report identifying which of the six domains drives this acceleration and to what degree.\u003c\/p\u003e\n\n\u003ch3\u003eWhat metabolic biomarkers detect insulin resistance before HbA1c elevation?\u003c\/h3\u003e\n\u003cp\u003eHbA1c reflects average blood glucose over 90 days and only rises above the pre-diabetic threshold (39 mmol\/mol) after substantial beta-cell compensation failure has already occurred. Insulin resistance — the upstream driver of type 2 diabetes — is detectable years earlier through fasting insulin and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance: fasting glucose mmol\/L × fasting insulin mIU\/L ÷ 22.5). HOMA-IR above 2.5 indicates clinically significant insulin resistance in Asian populations (lower threshold than 3.0 used in European populations, reflecting the differential metabolic susceptibility of Singapore's multi-ethnic population). The Triglyceride-to-HDL ratio (TG\/HDL-C) above 1.3 mmol\/L in Asian populations is a validated surrogate for LDL particle density and insulin resistance burden. GGT elevation (above 25 U\/L in women, 40 U\/L in men) reflects hepatic lipid accumulation and oxidative stress preceding NAFLD diagnosis. LinAge2's metabolic health age integrates these pre-HbA1c insulin resistance markers to identify metabolic ageing at the stage when intervention is most effective — before the pancreatic beta-cell exhaustion that makes HbA1c-detected pre-diabetes substantially harder to reverse.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Product\",\"name\":\"LinAge2 Comprehensive Health Age Screen\",\"description\":\"EMIS+ multi-dimensional biological age assessment. Six domains: epigenetic age (GrimAge\/PhenoAge), cardiovascular age (ApoB\/Lp(a)\/NT-proBNP), metabolic age (HOMA-IR\/HbA1c), hormonal age (testosterone LC-MS\/MS\/DHEA-S\/IGF-1), immune age (immunosenescence markers\/SASP\/NAD+), neurological age (NfL\/GFAP\/BDNF\/cognitive battery). Integrated Health Age Score + personalised longevity protocol. ISO 15189:2022. SGD 980. Singapore.\",\"brand\":{\"@type\":\"Brand\",\"name\":\"EMIS+\"},\"offers\":{\"@type\":\"Offer\",\"priceCurrency\":\"SGD\",\"price\":\"980.00\",\"availability\":\"https:\/\/schema.org\/InStock\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Essential Medical International Supplies Pte Ltd\",\"url\":\"https:\/\/www.emis.asia\"}},\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"Assessment Domains\",\"value\":\"6: epigenetic, cardiovascular, metabolic, hormonal, immune, neurological\"},{\"@type\":\"PropertyValue\",\"name\":\"Neurological Markers\",\"value\":\"Plasma NfL, GFAP, BDNF, cognitive function battery\"},{\"@type\":\"PropertyValue\",\"name\":\"Immune Markers\",\"value\":\"CD28-\/CD57+ T-cell ratio, SASP cytokines, NAD+ HPLC-MS\"},{\"@type\":\"PropertyValue\",\"name\":\"Laboratory Standard\",\"value\":\"ISO 15189:2022 medical laboratory accreditation\"},{\"@type\":\"PropertyValue\",\"name\":\"Output\",\"value\":\"Integrated Health Age Score + system-by-system deviation ranking\"},{\"@type\":\"PropertyValue\",\"name\":\"Location\",\"value\":\"Singapore\"}]}\u003c\/script\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory \u0026amp; Standards Framework:\u003c\/strong\u003e All laboratory analyses under \u003cstrong\u003eISO 15189:2022\u003c\/strong\u003e (Medical laboratories — Requirements for quality and competence). Hormonal assays per \u003cstrong\u003eCDC Hormone Standardisation (HoSt) Program\u003c\/strong\u003e. Cardiovascular biomarkers (ApoB, Lp(a)) per \u003cstrong\u003eWHO\/IFCC International Reference Preparations\u003c\/strong\u003e. Cognitive function battery per validated neuropsychological assessment frameworks (RBANS, MoCA). Plasma NfL and GFAP assays (Quanterix Simoa HD-X platform or equivalent ultra-sensitive immunoassay). GrimAge\/PhenoAge: Lu AT et al., \u003cem\u003eNature Aging\u003c\/em\u003e 2019; Levine ME et al., \u003cem\u003eAging\u003c\/em\u003e 2018. Plasma NfL and neurodegeneration: Preische O et al., \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e 2019. GFAP and amyloid prediction: Benedet AL et al., \u003cem\u003eJAMA Neurology\u003c\/em\u003e 2021. Singapore MOH regulated clinical laboratory and nursing services environment; EMIS+ nurses registered under Singapore Nursing Board (SNB).\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of LinAge2 Comprehensive Health Age Screen for digestive health?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen by EMIS + supports digestive health and gut wellbeing. For individuals with digestive concerns such as IBS, bloating, or irregular bowel habits, targeted gut health supplementation may complement a balanced diet and lifestyle. Always consult a doctor or dietitian before starting supplements for digestive conditions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take LinAge2 Comprehensive Health Age Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen may benefit adults seeking to support digestive health, those recovering from antibiotic use, individuals with irregular bowel habits, or those with conditions affecting gut microbiome balance. It is not a substitute for medical treatment. Consult your GP or gastroenterologist — available at SGH, NUH, Mount Elizabeth, and Raffles Hospital in Singapore — for personalised advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How should I take LinAge2 Comprehensive Health Age Screen for best results?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the LinAge2 Comprehensive Health Age Screen packaging or as directed by your healthcare provider. Consistency is key — most gut health supplements take 4–8 weeks of regular use to show measurable benefits. Store as directed on the label. Do not exceed the recommended daily dose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy LinAge2 Comprehensive Health Age Screen in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"LinAge2 Comprehensive Health Age Screen is available at EMIS+ (emis.asia) with fast Singapore island-wide delivery. We carry a curated range of clinically-informed digestive health supplements. Visit emis.asia or contact our team for product recommendations.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525722472526,"sku":null,"price":980.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"trueage-cellular-baseline","title":"TrueAge Cellular Baseline","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The TrueAge Cellular Baseline is an epigenetic age assessment service that quantifies biological age via genome-wide DNA methylation analysis across 900,000+ CpG sites, applying validated longevity clocks including GrimAge, PhenoAge, and the Horvath clock to establish an individual's true cellular ageing rate. The test is processed by a CLIA-certified laboratory and benchmarks results against population-level methylation reference datasets to identify discordance between chronological and biological age. It is indicated for longevity medicine practitioners, preventive health programmes, and individuals undertaking targeted anti-ageing interventions who require a quantitative cellular baseline prior to and following lifestyle or therapeutic modifications.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe TrueAge Cellular Baseline is a foundational epigenetic assessment available through EMIS+ in Singapore, designed to measure biological age at the molecular level using DNA methylation — the most validated epigenetic mechanism of cellular ageing. Unlike conventional blood biomarker panels, DNA methylation patterns across specific CpG loci change predictably and reproducibly with age, and deviations from expected methylation trajectories correlate with increased all-cause mortality, cardiometabolic disease burden, and functional decline. The test analyses over 900,000 CpG methylation sites to compute multiple validated biological age metrics, providing an objective and quantitative assessment of how rapidly an individual is ageing at the cellular level relative to chronological age.\u003c\/p\u003e\n\u003cp\u003eThe assessment employs the Illumina EPIC microarray platform within a CLIA-certified and HIPAA-compliant laboratory environment, ensuring analytical validity, chain-of-custody documentation, and data protection standards consistent with international clinical laboratory requirements. Results are interpreted via five established epigenetic clocks — GrimAge v2 (most predictive of all-cause mortality), PhenoAge (correlated with phenotypic age), Horvath v1 and v2 (pan-tissue clocks), and DunedinPACE (current pace of ageing) — alongside an immune cell composition report derived from methylation-based cell deconvolution. This multi-clock approach eliminates single-clock bias and enables nuanced longitudinal tracking of cellular ageing velocity over time.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\" cellspacing=\"0\" cellpadding=\"8\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eService Provider\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTruDiagnostic (Lexington, KY, USA); distributed by EMIS + Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAnalytical Platform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIllumina Infinium MethylationEPIC BeadChip (850K+ CpG sites)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eEpigenetic Clocks Reported\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrimAge v2, PhenoAge, Horvath v1\/v2, DunedinPACE, PCPhenoAge\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCpG Sites Analysed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e900,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSample Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePeripheral blood (dried blood spot or venepuncture)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4–6 weeks from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCLIA-certified (Certificate of Compliance); HIPAA-compliant data handling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eISO Compliance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLaboratory operations aligned with ISO 15189:2022 principles for medical laboratory quality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status (Singapore)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWellness and longevity assessment service; not an IVD medical device under HSA Health Products Act 2007\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReports Included\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBiological age, pace of ageing, organ system age (11 systems), immune cell deconvolution, telomere length estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReference Population\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMulti-ethnic population cohort (10,000+ samples); Asian-representative subgroup included\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications and Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eLongevity medicine baseline:\u003c\/strong\u003e Establishing a quantitative epigenetic age baseline for individuals entering structured anti-ageing or longevity optimisation programmes, enabling objective tracking of cellular age response to interventions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic and cardiometabolic risk stratification:\u003c\/strong\u003e Identifying biological age acceleration in individuals with normal clinical markers but elevated epigenetic risk scores, particularly GrimAge discordance, which is independently predictive of cardiovascular events.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCorporate preventive health programmes:\u003c\/strong\u003e Integration into executive health screening packages in Singapore where employers seek objective biological age data to complement conventional health screening panels.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-intervention efficacy monitoring:\u003c\/strong\u003e Paired baseline and follow-up testing (recommended at 6–12 month intervals) to quantify cellular age response to caloric restriction, exercise protocols, metformin, NMN\/NAD+ supplementation, or senolytics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune ageing and immunosenescence assessment:\u003c\/strong\u003e Methylation-based immune cell deconvolution to evaluate the ratio of naive to exhausted T-cell populations, relevant in oncology surveillance, post-COVID recovery programmes, and vaccine response evaluation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre-surgical and anaesthetic risk refinement:\u003c\/strong\u003e Supplementary biological age data for anaesthetists assessing frailty and physiological reserve in patients whose chronological age does not reflect functional status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How does DNA methylation-based biological age differ from telomere length testing?\u003c\/strong\u003e\u003cbr\u003eA: Telomere length testing measures the average length of chromosome end-caps and is subject to significant inter-cell variability and technical noise. DNA methylation clocks analyse specific CpG locus patterns across hundreds of thousands of genomic sites, providing a more reproducible and statistically robust measurement. GrimAge, in particular, has been validated in multiple prospective cohort studies as the strongest epigenetic predictor of all-cause mortality, outperforming telomere length and most conventional biomarkers for this application.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What is the clinical significance of a biological age that exceeds chronological age?\u003c\/strong\u003e\u003cbr\u003eA: Epigenetic age acceleration — where biological age is greater than chronological age — has been associated with increased risk of type 2 diabetes, cardiovascular disease, neurodegeneration, and all-cause mortality in meta-analyses involving hundreds of thousands of participants. A discordance of more than 3–5 years is generally considered clinically meaningful and warrants investigation of modifiable lifestyle, metabolic, and inflammatory factors. Practitioners should interpret results in the context of full clinical assessment rather than in isolation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How is the TrueAge Cellular Baseline conducted in Singapore?\u003c\/strong\u003e\u003cbr\u003eA: The service is fulfilled through EMIS+ in Singapore. Following purchase, a collection kit is dispatched; the blood sample can be collected via a home dried-blood-spot kit or at a participating phlebotomy centre. Samples are shipped to the TruDiagnostic CLIA-certified laboratory in the United States, with results returned digitally via a secure portal within 4–6 weeks of sample receipt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Is this test registered with the Health Sciences Authority (HSA) Singapore?\u003c\/strong\u003e\u003cbr\u003eA: The TrueAge Cellular Baseline is a wellness and longevity assessment service rather than an in vitro diagnostic (IVD) medical device as defined under the HSA Health Products (Medical Devices) Regulations 2010. It is not used for the diagnosis, monitoring, or treatment of a specific disease and therefore does not require product registration with HSA. Practitioners should communicate this distinction to patients, particularly in clinical contexts requiring regulatory-grade diagnostics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What is the recommended testing frequency for longitudinal tracking?\u003c\/strong\u003e\u003cbr\u003eA: The consensus recommendation from longevity medicine practitioners and the scientific advisory board of TruDiagnostic is to retest at 6–12 month intervals following baseline assessment. This interval is aligned with the timescale over which meaningful epigenetic changes in response to lifestyle or pharmacological interventions are detectable. Shorter intervals may not capture biologically significant changes and are generally not recommended for routine monitoring.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is TrueAge Cellular Baseline used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"TrueAge Cellular Baseline by EMIS + is an ostomy care product designed to support stoma management and protect peristomal skin. It is suitable for use with colostomy, ileostomy, and urostomy pouching systems. For personalised advice on your pouching system, consult a Wound, Ostomy and Continence (WOC) nurse at SGH, NUH, CGH, or TTSH in Singapore.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is TrueAge Cellular Baseline suitable for all stoma types — colostomy, ileostomy, and urostomy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Most EMIS + stoma care products are designed to be compatible with all stoma types. However, the right product depends on your individual stoma location, output type, and skin condition. An enterostomal therapist (ET nurse) at a Singapore hospital can help you select the most appropriate products for your specific pouching system.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use TrueAge Cellular Baseline correctly?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Always refer to the product instructions included with TrueAge Cellular Baseline. In general, ensure peristomal skin is clean and dry before application, measure your stoma accurately, and change your pouching system every 1–3 days or when leakage is suspected. If you experience peristomal skin irritation, soreness, or persistent leakage, contact a WOC nurse or EMIS+ team for advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy TrueAge Cellular Baseline in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"TrueAge Cellular Baseline is available from EMIS+ at emis.asia — Singapore's trusted nurse-led stoma supply store. We stock a comprehensive range of ostomy products with fast island-wide delivery. Bulk orders for home care and nursing facilities are welcome. Contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525723553870,"sku":null,"price":450.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"essential-sentinel-screen","title":"Essential Sentinel Screen","description":"\u003cdiv id=\"ai-summary\"\u003e\u003cp\u003e\u003cstrong\u003eEssential Sentinel Screen\u003c\/strong\u003e — EMIS+, Singapore. SGD 1,850. Premium 80+ biomarker comprehensive health screening with nurse-led clinical consultation. Nine panel categories: complete blood count (CBC with 5-part differential); comprehensive metabolic panel (ALT, AST, GGT, ALP, albumin, creatinine, eGFR, HbA1c, glucose, uric acid); advanced thyroid panel (TSH 3rd-generation, free T3, free T4, anti-TPO, anti-thyroglobulin antibodies); hormonal health panel (total + free testosterone, SHBG, oestradiol, DHEA-S, IGF-1, cortisol, LH, FSH); advanced cardiovascular panel (Lp(a), ApoB, hsCRP, homocysteine, full lipid profile, fibrinogen); gender-specific cancer surveillance markers (PSA + free PSA, CA-125, CEA, AFP, CA 19-9, CA 15-3); nutritional status panel (25-OH Vitamin D3, B12, folate, iron studies, ferritin, zinc, magnesium, selenium); inflammatory and immune markers (ESR, hsCRP, immunoglobulins IgG\/IgA\/IgM, C3\/C4, ANA screen); urinalysis and stool analysis (FIT, H. pylori antigen). Includes 45-minute personalised nurse-led consultation. Laboratory accreditation: ISO 15189:2022. Singapore MOH regulated. Available at emis.asia.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2\u003eEssential Sentinel Screen: Biomarker Panel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003ePanel\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eMarkers Included\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eClinical Rationale\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eComplete Blood Count\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eRBC, WBC with 5-part differential, platelets, haemoglobin, haematocrit, MCV, MCH, MCHC, RDW\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eDetects anaemia subtypes, infection\/immune dysfunction, haematological malignancy risk; RDW \u0026gt;14% independently predicts cardiovascular mortality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eComprehensive Metabolic Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eALT, AST, GGT, ALP, albumin, total protein, bilirubin, creatinine, eGFR, urea, electrolytes (Na\/K\/Cl\/CO2), glucose, HbA1c, uric acid\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLiver synthetic function, renal filtration rate (KDIGO staging); HbA1c 39–47 mmol\/mol detects pre-diabetes; eGFR \u0026lt;60 mL\/min\/1.73m2 = CKD Stage 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eAdvanced Thyroid Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTSH (3rd generation, sensitivity 0.01 mIU\/L), free T3, free T4, anti-TPO antibodies, anti-thyroglobulin antibodies\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eAnti-TPO positivity predicts progression to overt hypothyroidism at ~4%\/year; subclinical hypothyroidism affects 8–10% of adults; free T3 correlates with metabolic rate and cardiac output\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eHormonal Health Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal testosterone (LC-MS\/MS), free testosterone (calculated), SHBG, oestradiol (E2), DHEA-S, IGF-1, cortisol (morning), LH, FSH\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTestosterone \u0026lt;12 nmol\/L (men): 2.3× all-cause mortality; low DHEA-S correlates with accelerated immune ageing; IGF-1 regulates anabolic metabolism and tissue repair\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eAdvanced Cardiovascular Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB, Lp(a), hsCRP, homocysteine, fibrinogen\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLp(a) \u0026gt;50 mg\/dL: 3× ASCVD risk; ApoB preferred over LDL-C per ACC\/AHA 2023; homocysteine \u0026gt;15 micromol\/L: 2× stroke risk; hsCRP \u0026gt;3 mg\/L: high inflammatory cardiovascular risk tier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eCancer Surveillance Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ePSA total + free ratio (men), CA-125 (women), CEA, AFP, CA 19-9, CA 15-3\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eInterpreted via trend and clinical context, not standalone diagnosis; PSA velocity and free\/total PSA ratio improve prostate cancer specificity; CEA elevated in colorectal and lung malignancy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNutritional Status Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e25-OH Vitamin D3, B12, folate, serum iron, TIBC, ferritin, zinc, magnesium, selenium\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e25-OH D3 \u0026lt;50 nmol\/L affects 65–80% of Singapore adults; ferritin \u0026lt;30 microg\/L = pre-anaemic iron depletion; B12 \u0026lt;200 pmol\/L prevalent in vegetarians and metformin users\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eInflammatory \u0026amp; Immune Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eESR, hsCRP, ferritin, immunoglobulins (IgG, IgA, IgM), complement C3\/C4, ANA screen (IIF, HEp-2 cells)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eANA titre \u0026gt;1:160 with clinical features warrants reflex anti-dsDNA, anti-Sm, anti-Ro\/La testing; chronic low-grade inflammation underlies 7 of 10 leading causes of mortality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eUrinalysis \u0026amp; Stool Analysis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eUrine dipstick + microscopy (protein, blood, glucose, leucocytes, casts, microalbuminuria), FIT stool occult blood, H. pylori stool antigen\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eMicroalbuminuria 30–300 mg\/g predicts diabetic nephropathy 5–10 years pre-onset; FIT detects colorectal adenomas with 79% sensitivity; H. pylori eradication reduces gastric cancer risk 34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNurse-Led Consultation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e45-minute one-on-one results review with EMIS+ registered nurse; personalised health optimisation plan\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eResults interpreted in context of health history, lifestyle, medications; triggers referral pathways; actionable 90-day health plan covering nutrition, exercise, supplementation, and monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eClinical Q\u0026amp;A: Essential Sentinel Screen\u003c\/h2\u003e\n\n\u003ch3\u003eWhy does the Essential Sentinel Screen include Lp(a) and ApoB when most screenings only measure LDL-C?\u003c\/h3\u003e\n\u003cp\u003eLDL-C (low-density lipoprotein cholesterol) is a concentration measure that underestimates cardiovascular risk in individuals with small, dense LDL particles or discordant ApoB levels. ApoB measures the number of atherogenic particles directly — each VLDL, IDL, and LDL particle carries exactly one ApoB molecule — making it a superior predictor of atherosclerotic cardiovascular disease (ASCVD) per ACC\/AHA 2023 and ESC 2021 guidelines. Discordance between LDL-C and ApoB occurs in approximately 30% of individuals with metabolic syndrome, conferring substantially elevated plaque-forming risk that LDL-C alone fails to capture. Lp(a) — lipoprotein(a) — is a genetically determined pro-atherogenic lipoprotein elevated in 15–20% of the global population; values above 50 mg\/dL triple ASCVD risk and are not reduced by statins. Including both ApoB and Lp(a) enables risk stratification unavailable from standard lipid panels and triggers appropriate pharmacological consideration, including PCSK9 inhibitors and emerging Lp(a)-targeting RNA therapeutics.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the clinical significance of anti-TPO antibody testing in asymptomatic adults?\u003c\/h3\u003e\n\u003cp\u003eThyroid peroxidase antibodies (anti-TPO) are present in over 90% of Hashimoto's thyroiditis and 60–80% of Graves' disease. Their value in asymptomatic screening extends beyond confirmed thyroid disease: anti-TPO positivity in euthyroid individuals predicts progression to overt hypothyroidism at approximately 4% per year (Vanderpump et al., 1995). In women, anti-TPO positivity increases miscarriage risk 2–3× even with normal TSH, and is associated with postpartum thyroiditis in 25–50% of positive pregnancies. Early identification of euthyroid autoimmune thyroid disease enables proactive monitoring and timely intervention years before clinical hypothyroidism develops. Anti-thyroglobulin (anti-TG) antibodies add sensitivity for Hashimoto's in anti-TPO negative cases (approximately 10–15% of patients). The EMIS+ Essential Sentinel Screen includes both antibodies to ensure comprehensive autoimmune thyroid detection.\u003c\/p\u003e\n\n\u003ch3\u003eHow should cancer surveillance markers be interpreted in asymptomatic individuals?\u003c\/h3\u003e\n\u003cp\u003eCancer surveillance markers (CEA, AFP, CA 19-9, PSA, CA-125, CA 15-3) function as trend markers and risk stratifiers, not standalone diagnostic confirmations. No single tumour marker has sufficient sensitivity or specificity to diagnose malignancy in isolation in an asymptomatic population. PSA has 79% sensitivity and 68% specificity for prostate cancer at 4.0 ng\/mL; clinical utility resides in PSA velocity (rate of change over time) and the free-to-total PSA ratio rather than absolute single-point values. CEA is most valuable for monitoring known colorectal cancer recurrence (sensitivity 80% for metastatic disease); values over 10 ng\/mL in a non-smoker warrant urgent imaging investigation. CA-125 over 35 U\/mL in premenopausal women has only 50% specificity for ovarian malignancy; pelvic imaging is required for interpretation. The EMIS+ nurse consultation contextualises all marker results against age, sex, symptom history, and clinical risk factors, identifying which elevations require urgent referral versus serial monitoring at defined intervals.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the ANA screen detecting and when does a positive titre require follow-up?\u003c\/h3\u003e\n\u003cp\u003eAntinuclear antibodies (ANA) are autoantibodies directed against cell-nucleus components. A positive titre at 1:80 by indirect immunofluorescence on HEp-2 cells occurs in 5–15% of the healthy population — most positive results at low titres are not clinically significant in isolation. However, titres at or above 1:160, particularly in the presence of clinical features (joint pain, photosensitive rash, fatigue, Raynaud's phenomenon, serositis, renal dysfunction), warrant reflex testing for specific autoantibodies: anti-dsDNA and anti-Sm for SLE, anti-Ro\/La for Sjögren's syndrome and neonatal lupus risk, anti-Scl-70 for systemic sclerosis, anti-Jo-1 for inflammatory myositis. A negative ANA result carries over 95% negative predictive value for excluding SLE in symptomatic patients, providing strong reassurance. EMIS+ nurses interpret ANA titres in the context of your symptom history, with defined criteria for rheumatology referral.\u003c\/p\u003e\n\n\u003ch3\u003eHow does the nutritional panel address Singapore-specific micronutrient deficiency patterns?\u003c\/h3\u003e\n\u003cp\u003eThree high-prevalence deficiencies documented in Singapore population surveys require proactive screening in all adults. Vitamin D insufficiency (25-OH D3 below 50 nmol\/L) affects 65–80% of Singapore adults due to the combined effect of indoor lifestyle, deliberate sun avoidance, and the higher UV exposure required for cutaneous synthesis in darker skin phototypes; optimal range for immune regulation, bone mineral density, and cancer risk reduction is 75–125 nmol\/L. Iron depletion without anaemia (ferritin below 30 microg\/L with normal haemoglobin) affects 15–25% of premenopausal women and presents as fatigue, impaired cognitive performance, and reduced aerobic capacity 6–12 months before haemoglobin falls below reference range — making full blood count alone systematically insufficient for iron status assessment. Vitamin B12 insufficiency (below 200 pmol\/L) occurs in 12–18% of Singapore vegetarians and 20–30% of long-term metformin users, as metformin competitively inhibits ileal B12 absorption via the calcium-dependent transporter. The EMIS+ Essential Sentinel Screen captures all three with quantified severity, enabling calibrated supplementation protocols based on measured deficit rather than population-average assumptions.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Product\",\"name\":\"Essential Sentinel Screen\",\"description\":\"EMIS+ premium comprehensive health screening — 80+ biomarkers across 9 organ system panels: CBC, metabolic, thyroid, hormonal, cardiovascular (ApoB\/Lp(a)), cancer surveillance, nutritional, inflammatory\/immune, urinalysis and stool. Includes 45-minute nurse-led consultation. ISO 15189:2022 accredited. Singapore.\",\"brand\":{\"@type\":\"Brand\",\"name\":\"EMIS+\"},\"offers\":{\"@type\":\"Offer\",\"priceCurrency\":\"SGD\",\"price\":\"1850.00\",\"availability\":\"https:\/\/schema.org\/InStock\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Essential Medical International Supplies Pte Ltd\",\"url\":\"https:\/\/www.emis.asia\"}},\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"Total Biomarkers\",\"value\":\"80+ across 9 panel categories\"},{\"@type\":\"PropertyValue\",\"name\":\"Laboratory Standard\",\"value\":\"ISO 15189:2022 medical laboratory accreditation\"},{\"@type\":\"PropertyValue\",\"name\":\"Consultation Included\",\"value\":\"45-minute nurse-led clinical consultation\"},{\"@type\":\"PropertyValue\",\"name\":\"Cardiovascular Markers\",\"value\":\"ApoB, Lp(a), hsCRP, homocysteine\"},{\"@type\":\"PropertyValue\",\"name\":\"Cancer Markers\",\"value\":\"PSA, CA-125, CEA, AFP, CA 19-9, CA 15-3\"},{\"@type\":\"PropertyValue\",\"name\":\"Location\",\"value\":\"Singapore\"}]}\u003c\/script\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory \u0026amp; Standards Framework:\u003c\/strong\u003e All laboratory analyses performed under \u003cstrong\u003eISO 15189:2022\u003c\/strong\u003e (Medical laboratories — Requirements for quality and competence). Hormonal assays (testosterone LC-MS\/MS) validated per \u003cstrong\u003eCDC Hormone Standardisation (HoSt) Program\u003c\/strong\u003e reference standards. Thyroid function tests (TSH, free T3\/T4) referenced to \u003cstrong\u003eIFCC\/NACB Laboratory Medicine Practice Guidelines\u003c\/strong\u003e. Cardiovascular biomarkers (ApoB, Lp(a)) standardised to \u003cstrong\u003eWHO International Reference Preparations\u003c\/strong\u003e (IFCC Reference Material 2nd IS for Lp(a); WHO\/IFCC Reference Preparation SP3-07 for ApoB). Cancer marker methodology per \u003cstrong\u003eEGTM (European Group on Tumour Markers) guidelines\u003c\/strong\u003e. Anti-nuclear antibody testing by indirect immunofluorescence (IIF) on HEp-2 cells per \u003cstrong\u003eACR\/EULAR 2019 classification criteria\u003c\/strong\u003e. Singapore Ministry of Health (MOH) regulated clinical laboratory environment. \u003cstrong\u003eISO 22870:2016\u003c\/strong\u003e (Point-of-care testing) compliance maintained throughout.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Essential Sentinel Screen?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Essential Sentinel Screen product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Essential Sentinel Screen in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Essential Sentinel Screen is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525775589454,"sku":null,"price":1850.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"vivere-advanced-cellular-blueprint","title":"Advanced Cellular Blueprint","description":"\u003cdiv id=\"ai-summary\"\u003e\u003cp\u003e\u003cstrong\u003eAdvanced Cellular Blueprint\u003c\/strong\u003e — EMIS+, Singapore. SGD 1,950. Flagship multi-domain longevity assessment profiling six biological ageing mechanisms simultaneously: (1) epigenetic biological age via DNA methylation clocks (GrimAge, PhenoAge, Horvath); (2) telomere length by quantitative PCR (T\/S ratio); (3) intracellular NAD+ by HPLC-tandem mass spectrometry; (4) cellular senescence burden — p16INK4a mRNA expression and SASP cytokine panel (IL-6, IL-8, GDF-15, MMP-3, TNF-alpha); (5) advanced cardiometabolic panel — LDL particle number, Lp(a), ApoB, hsCRP, homocysteine, HbA1c, insulin, HOMA-IR; (6) hormonal longevity panel — total and free testosterone, DHEA-S, IGF-1, free T3\/T4, TSH, cortisol. Output: composite biological age index across all six domains with ranked deviation from age-matched reference ranges and a nurse-curated personalised longevity protocol. Laboratory accreditation: ISO 15189:2022. Singapore Ministry of Health (MOH) regulated clinical laboratory services. Available exclusively at emis.asia.\u003c\/p\u003e\u003c\/div\u003e\n\n\u003ch2\u003eAdvanced Cellular Blueprint: Assessment Panel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eAssessment Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eBiomarkers \/ Method\u003c\/th\u003e\n\u003cth style=\"padding:10px 12px;text-align:left;border:1px solid #004a91;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eEpigenetic Biological Age\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eDNA methylation clocks: GrimAge, PhenoAge, Horvath; Illumina EPIC array or bisulfite sequencing\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ePredicts all-cause mortality risk; 1-year epigenetic age acceleration ≈ 4–8% mortality increase (Lu et al., Nature Aging 2019)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eTelomere Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eqPCR T\/S ratio; leukocyte telomere length vs. age-matched reference population\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eShort telomeres: 1.3–1.9× increased cardiovascular and cancer risk; tracks replicative lifespan capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eIntracellular NAD+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eHPLC-tandem mass spectrometry; whole-blood NAD+\/NADH ratio\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eNAD+ declines ~50% per decade from age 40; drives SIRT1\/PARP1 DNA repair; NMN\/NR supplementation efficacy marker\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eCellular Senescence Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003ep16INK4a mRNA expression; SASP cytokines: IL-6, IL-8, GDF-15, MMP-3, TNF-alpha\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eElevated p16INK4a correlates with accelerated tissue ageing; SASP drives chronic inflammageing and age-related disease progression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eAdvanced Cardiometabolic Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLDL particle number (NMR), Lp(a), ApoB, hsCRP, homocysteine, HbA1c, fasting insulin, HOMA-IR\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLp(a) \u0026gt;50 mg\/dL: 3× cardiovascular risk; ApoB superior to LDL-C for ASCVD prediction per ACC\/AHA 2023 guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eHormonal Longevity Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eTotal + free testosterone (LC-MS\/MS), DHEA-S, IGF-1, free T3, free T4, TSH, cortisol AM\/PM\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eLow testosterone \u0026lt;12 nmol\/L: 2.3× all-cause mortality in men; DHEA-S declines 80% from age 25 to 70\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eMitochondrial Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e8-OHdG (oxidative DNA damage), MDA (lipid peroxidation), CoQ10, SOD activity, citrate synthase\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eMitochondrial dysfunction underlies 9 of 12 hallmarks of ageing; oxidative stress biomarkers predict functional decline trajectory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eComposite Biological Age Index\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eWeighted multi-domain algorithm; deviation from Singapore-population age-matched norms\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eSingle integrated biological age number + domain-by-domain ranking; identifies highest-impact intervention targets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f5f8ff;\"\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e\u003cstrong\u003eNurse-Led Consultation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003e60-minute one-on-one results review; personalised longevity protocol (EMIS+ registered nurse)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 12px;border:1px solid #dde4f0;\"\u003eEvidence-based intervention plan: nutrition, exercise prescription, sleep optimisation, supplementation, and medical referral where indicated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eClinical Q\u0026amp;A: Advanced Cellular Blueprint\u003c\/h2\u003e\n\n\u003ch3\u003eHow does epigenetic biological age differ from chronological age, and why does it matter more?\u003c\/h3\u003e\n\u003cp\u003eChronological age is simply the number of years since birth. Epigenetic biological age measures chemical modifications to DNA — specifically methylation patterns at CpG sites — that accumulate at rates determined by lifestyle, environment, and disease burden. The GrimAge clock, derived from 1,030 individuals and validated in over 10,000 subjects, predicts time-to-death more accurately than any single traditional biomarker. A 5-year epigenetic age acceleration (biological age 5 years older than chronological age) corresponds to approximately a 16–21% increase in all-cause mortality risk. Conversely, measurable epigenetic age deceleration has been demonstrated following caloric restriction, aerobic exercise training, and certain pharmacological interventions, confirming these clocks respond to modifiable factors rather than representing fixed genetic fate.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is cellular senescence and how does SASP contribute to disease progression?\u003c\/h3\u003e\n\u003cp\u003eCellular senescence is a state of permanent cell-cycle arrest — cells that have lost the ability to divide but remain metabolically active and resist apoptosis. Senescent cells accumulate with age and following genotoxic stress (UV, chemotherapy, oxidative damage). They secrete a complex pro-inflammatory milieu termed the Senescence-Associated Secretory Phenotype (SASP): interleukins (IL-6, IL-8), matrix metalloproteinases (MMP-3), growth factors (GDF-15), and TNF-alpha. This SASP propagates senescence to neighbouring cells, disrupts tissue architecture, drives chronic sterile inflammation (inflammageing), and creates a tumour-permissive microenvironment. p16INK4a mRNA expression in peripheral blood mononuclear cells is the most validated circulating senescence biomarker, rising exponentially from age 35 onwards. Emerging senolytics (dasatinib + quercetin, fisetin) specifically clear senescent cells and have shown preclinical efficacy across multiple age-related pathologies.\u003c\/p\u003e\n\n\u003ch3\u003eWhat NAD+ level warrants intervention, and which repletion strategy has the strongest evidence?\u003c\/h3\u003e\n\u003cp\u003eIntracellular NAD+ measured by HPLC-MS in whole blood declines from approximately 40–50 micromolar at age 30 to 20–25 micromolar by age 60 — a ~50% reduction that impairs SIRT1-mediated deacetylation, PARP1-dependent DNA repair, and CD38-regulated calcium signalling. Functional NAD+ insufficiency presents as declining metabolic flexibility, impaired stress response, and accumulating genomic instability. Clinical trials support NMN (nicotinamide mononucleotide) at 250–900 mg\/day increasing whole-blood NAD+ by 38–90% over 12 weeks (Yoshino et al., 2021; Igarashi et al., 2022). NR (nicotinamide riboside) at 300–1,000 mg\/day similarly raises NAD+ 40–60%. The Advanced Cellular Blueprint baseline enables personalised dosing and monitoring of NMN\/NR supplementation efficacy, transforming supplementation from guesswork into measurable biochemistry.\u003c\/p\u003e\n\n\u003ch3\u003eHow is telomere length interpreted clinically, and what lifestyle factors most reliably preserve it?\u003c\/h3\u003e\n\u003cp\u003eTelomere length is reported as a T\/S ratio (telomere repeat copy number to single-copy gene ratio) and compared against age-sex-matched population percentiles. Leukocyte telomere length in the lowest quartile for age is associated with 1.5–1.9× increased risk of cardiovascular disease and 1.3× all-cause mortality. Critically, intra-individual rate of telomere attrition over serial measurements predicts disease trajectory better than a single cross-sectional value. Lifestyle interventions with the strongest evidence for telomere preservation include: vigorous aerobic exercise (VO2 max training) reducing attrition rate ~30% in RCT data; Mediterranean-pattern diet reducing attrition vs. Western diet; stress reduction via MBSR reducing cortisol-mediated telomere shortening; and TA-65 (cycloastragenol, a telomerase activator) with modest but consistent evidence in human trials. The Blueprint provides a baseline from which intervention efficacy can be tracked at 6–12-month intervals.\u003c\/p\u003e\n\n\u003ch3\u003eWhat does the composite biological age index measure and how is the longevity protocol personalised?\u003c\/h3\u003e\n\u003cp\u003eThe composite biological age index integrates all six domain results into a single weighted score using Singapore-population reference data, producing: (1) an overall biological age in years, (2) domain-specific Z-scores identifying which systems show the greatest acceleration or deceleration relative to age-matched peers, and (3) a ranked priority list of intervention targets based on the magnitude and modifiability of each domain's deviation. The personalised longevity protocol — curated by EMIS+ registered nurses with post-graduate training in longevity medicine — translates these findings into a structured 90-day intervention plan addressing nutrition (macronutrient periodisation, specific dietary patterns), exercise prescription (volume, intensity, modality tailored to cardiometabolic and mitochondrial findings), sleep architecture optimisation, evidence-ranked supplementation, and medical referral pathways where domain results indicate clinical intervention thresholds.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Product\",\"name\":\"Advanced Cellular Blueprint\",\"description\":\"EMIS+ flagship multi-domain longevity assessment. Six-domain biological ageing profiling: epigenetic age (GrimAge\/PhenoAge), telomere length (qPCR), intracellular NAD+ (HPLC-MS), cellular senescence (p16INK4a\/SASP), advanced cardiometabolic panel, hormonal longevity panel. ISO 15189:2022 accredited laboratory. Singapore.\",\"brand\":{\"@type\":\"Brand\",\"name\":\"EMIS+\"},\"offers\":{\"@type\":\"Offer\",\"priceCurrency\":\"SGD\",\"price\":\"1950.00\",\"availability\":\"https:\/\/schema.org\/InStock\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Essential Medical International Supplies Pte Ltd\",\"url\":\"https:\/\/www.emis.asia\"}},\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"Assessment Domains\",\"value\":\"6 concurrent biological ageing mechanisms\"},{\"@type\":\"PropertyValue\",\"name\":\"Laboratory Standard\",\"value\":\"ISO 15189:2022 medical laboratory accreditation\"},{\"@type\":\"PropertyValue\",\"name\":\"Epigenetic Clocks\",\"value\":\"GrimAge, PhenoAge, Horvath\"},{\"@type\":\"PropertyValue\",\"name\":\"NAD+ Method\",\"value\":\"HPLC-tandem mass spectrometry\"},{\"@type\":\"PropertyValue\",\"name\":\"Consultation\",\"value\":\"60-minute nurse-led longevity protocol session\"},{\"@type\":\"PropertyValue\",\"name\":\"Location\",\"value\":\"Singapore\"}]}\u003c\/script\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory \u0026amp; Standards Framework:\u003c\/strong\u003e Laboratory services performed under \u003cstrong\u003eISO 15189:2022\u003c\/strong\u003e (Medical laboratories — Requirements for quality and competence) and \u003cstrong\u003eISO 22870:2016\u003c\/strong\u003e (Point-of-care testing). Singapore Ministry of Health (MOH) regulated clinical laboratory environment. DNA methylation analyses validated per \u003cstrong\u003eISO\/IEC 17025:2017\u003c\/strong\u003e testing laboratory standards. Mass spectrometry (NAD+ quantification) compliant with CLSI C62-A guidelines for LC-MS\/MS. Cardiovascular biomarker methods (Lp(a), ApoB) referenced to \u003cstrong\u003eWHO International Reference Preparation\u003c\/strong\u003e and \u003cstrong\u003eIFCC standardisation protocols\u003c\/strong\u003e. GrimAge\/PhenoAge epigenetic clocks: Lu AT et al., \u003cem\u003eNature Aging\u003c\/em\u003e 2019; Levine ME et al., \u003cem\u003eAging\u003c\/em\u003e 2018.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Advanced Cellular Blueprint used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Advanced Cellular Blueprint by EMIS + is a advanced wound dressing used for wound management. It is designed to support moist wound healing, manage exudate, and protect the wound bed from contamination. It is commonly used in Singapore hospitals and home care settings for chronic wounds, post-surgical wounds, and ulcers. Always follow the guidance of your wound care nurse or doctor when selecting a dressing.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How often should Advanced Cellular Blueprint be changed?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Advanced Cellular Blueprint should generally be changed every 1–7 days depending on wound type and exudate. However, frequency should always be guided by your wound care nurse or clinician based on wound size, exudate level, and signs of infection. Do not leave any dressing in place if it becomes saturated, dislodged, or if the wound shows signs of infection such as increased redness, warmth, or discharge.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Advanced Cellular Blueprint available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes, Advanced Cellular Blueprint is available for purchase from EMIS+ (emis.asia) without a prescription for general wound care use. For complex or chronic wounds, we strongly recommend consulting a wound care nurse, GP, or specialist at a Singapore hospital such as SGH, NUH, TTSH, or CGH before selecting a dressing. EMIS+ nurses can also provide product guidance — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Advanced Cellular Blueprint in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Advanced Cellular Blueprint is available from EMIS+ at emis.asia, Singapore's nurse-led medical supply store. We offer fast island-wide delivery, competitive pricing, and bulk ordering for healthcare facilities and home care users. Visit emis.asia or contact our team for assistance.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525988974670,"sku":null,"price":1950.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"heart-shield-elite","title":"Heart Shield Elite","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eHeart Shield Elite — Advanced 360° Cardiovascular Risk Assessment (SGD 899)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nHeart Shield Elite is EMIS+'s most comprehensive cardiovascular risk stratification protocol, integrating seven distinct biomarker domains, genetic polygenic risk scoring, non-invasive vascular imaging, and electrocardiographic assessment into a single coordinated clinical evaluation. The protocol quantifies both short-term (10-year Pooled Cohort Equations \/ SCORE2) and lifetime atherosclerotic cardiovascular disease (ASCVD) risk, then translates findings into a personalised cardiac protection protocol aligned with ACC\/AHA 2023, ESC\/EAS 2021, and Singapore MOH Cardiovascular Prevention Clinical Practice Guidelines.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eInflammatory and Cardiac Biomarker Panel:\u003c\/strong\u003e High-sensitivity C-reactive protein (hsCRP, IFCC-standardised, LoD ≤0.1 mg\/L) stratifies residual inflammatory risk beyond LDL-C control. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI, Roche Elecsys platform, 99th-percentile URL) screen for subclinical myocardial stress and early heart failure. Homocysteine (HPLC enzymatic, µmol\/L), fibrinogen (Clauss method, g\/L), and D-dimer (VIDAS immunoassay, µg\/mL FEU) complete the thromboinflammatory axis.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eAdvanced Lipid Panel:\u003c\/strong\u003e Beyond standard LDL-C, the protocol measures lipoprotein(a) [Lp(a), isoform-independent immunoturbidimetric assay, reported in nmol\/L per EAS Consensus Statement 2022], oxidised LDL (oxLDL, mU\/L, ELISA), apolipoprotein B (ApoB, g\/L, immunonephelometry — direct measure of atherogenic particle count), and apolipoprotein A-1 (ApoA-1, g\/L) with ApoB\/ApoA-1 ratio computed. These analytes identify atherogenic dyslipidaemia undetected by conventional LDL-C measurement.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGenetic Cardiovascular Polygenic Risk Score (CAD-PRS):\u003c\/strong\u003e A validated multi-SNP coronary artery disease polygenic risk score (CAD-PRS, ≥6.6 million SNPs, genome-wide chip genotyping) places the individual's inherited CAD susceptibility in population-referenced percentile tiers (quintiles\/deciles). Individuals in the top 5% carry risk equivalent to a monogenic familial hypercholesterolaemia mutation. Results are interpreted in conjunction with measured biomarkers per the American Heart Association 2023 Precision Medicine Advisory.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eArterial Stiffness — Pulse Wave Velocity (PWV):\u003c\/strong\u003e Carotid-femoral pulse wave velocity (cf-PWV, m\/s, applanation tonometry) measures aortic stiffness — an independent predictor of cardiovascular events validated in the CAFE, ADVANCE, and Framingham Offspring cohorts. Results are age\/sex\/blood-pressure-referenced per ESH\/ESC 2023 hypertension guidelines (pathological threshold: cf-PWV \u0026gt;10 m\/s).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCarotid Intima-Media Thickness (CIMT) Ultrasound:\u003c\/strong\u003e B-mode ultrasound of the common carotid artery bilateral segments (ASE\/EACVI 2008 protocol, automated edge-detection software) measures intima-media thickness in millimetres and identifies carotid atherosclerotic plaque. CIMT \u0026gt;75th age\/sex percentile reclassifies intermediate-risk individuals to high risk per ACC\/AHA 2018 guidelines; plaque presence is independently associated with 2× increased MACE risk (CAPS, Rotterdam Study, MESA).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eResting 12-Lead ECG:\u003c\/strong\u003e Physician-reported resting electrocardiogram screens for left ventricular hypertrophy (Sokolow-Lyon\/Cornell voltage criteria), ST-T abnormalities, conduction defects (LBBB, RBBB, fascicular blocks), QTc prolongation (Bazett\/Fridericia formula, ms), and arrhythmias including silent atrial fibrillation. ECG LVH independently adds predictive value for incident heart failure and stroke beyond conventional risk factors.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eComposite Risk Outputs:\u003c\/strong\u003e Heart Health Age (HHA) — the age of a normotensive, non-smoking, lipid-optimal reference individual carrying equivalent cardiovascular risk — is calculated from the full biomarker + imaging dataset. 10-year ASCVD risk is computed via Pooled Cohort Equations (PCE, ACC\/AHA 2013, updated 2023) and SCORE2 (European SCORE2 Working Group 2021) with reclassification where indicated. Lifetime ASCVD risk (Framingham Lifetime Risk model) contextualises risk for shared decision-making. All results delivered in a structured physician report with evidence-based intervention recommendations.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eHeart Shield Elite — Assessment Protocol Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:26%;\"\u003eAssessment Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:30%;\"\u003eAnalyte \/ Parameter\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eMethod \/ Platform\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eReference Standard\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eInflammatory Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ehsCRP (mg\/L), Fibrinogen (g\/L), Homocysteine (µmol\/L), IL-6 (pg\/mL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIFCC-standardised immunoassay; Clauss coagulation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; IFCC Reference Preparations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCardiac Biomarkers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNT-proBNP (pg\/mL), hs-cTnI (ng\/L), D-dimer (µg\/mL FEU)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRoche Elecsys electrochemiluminescence; VIDAS immunoassay\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESC 2021 HF Guidelines; ESC 2020 NSTEMI Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eAdvanced Lipid Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLp(a) (nmol\/L), ApoB (g\/L), ApoA-1 (g\/L), oxLDL (mU\/L), ApoB\/ApoA-1 ratio\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIsoform-independent immunoturbidimetry; ELISA (oxLDL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEAS Lp(a) Consensus 2022; ESC\/EAS Dyslipidaemia Guidelines 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGenetic CAD-PRS\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCoronary Artery Disease Polygenic Risk Score (≥6.6M SNPs)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eGenome-wide SNP chip; LDpred2 \/ PRSice-2 algorithm\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA 2023 Precision Medicine Advisory; Khera et al. NatGen 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eArterial Stiffness PWV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCarotid-femoral PWV (m\/s); Augmentation Index (AIx@75)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eApplanation tonometry (SphygmoCor)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESH\/ESC 2023 Hypertension Guidelines; Laurent et al. EHJ 2006\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCIMT Ultrasound\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCommon carotid IMT bilateral (mm); plaque characterisation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eB-mode ultrasound, automated edge detection (QIMT)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eASE\/EACVI 2008 Protocol; ACC\/AHA 2018 Cholesterol Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eElectrocardiography\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eResting 12-lead ECG: LVH criteria, QTc (ms), rhythm, ST-T changes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDigital ECG acquisition; physician interpretation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA\/ACC\/HRS 2009 ECG Standardisation; Bazett\/Fridericia QTc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eComposite Risk Scores\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHeart Health Age; 10-year ASCVD (PCE + SCORE2); Lifetime ASCVD Risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePooled Cohort Equations; SCORE2; Framingham Lifetime Risk Model\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eACC\/AHA 2013\/2023; SCORE2 Working Group EHJ 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eReport Deliverable\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIntegrated physician report; personalised cardiac protection protocol\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEvidence-based intervention recommendations\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSingapore MOH Cardiovascular Prevention CPG; ACC\/AHA 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022 medical laboratory; CAP-accredited partner sites\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eExternal quality assurance: EQAS, RIQAS, Bio-Rad Liquichek\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; Singapore HSA Laboratory Licensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e14–21 working days (all components)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eBlood draw + vascular imaging appointment\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eSingapore delivery; telehealth results review available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Heart Shield Elite\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is ApoB superior to LDL-C as a therapeutic target, and what does Heart Shield Elite add beyond a standard lipid panel?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eStandard LDL-C (Friedewald or Martin-Hopkins calculation) estimates the cholesterol mass within LDL particles but does not directly count atherogenic particles. Each LDL, IDL, VLDL, Lp(a), and chylomicron remnant carries exactly one apolipoprotein B molecule; therefore ApoB concentration is a direct, particle-number measure of atherogenic burden. Multiple Mendelian randomisation studies and the ApoB vs LDL-C Collaborative Analysis (JAMA 2021) demonstrate that ApoB is a stronger predictor of MACE than LDL-C, particularly in patients with metabolic syndrome, hypertriglyceridaemia, or insulin resistance — conditions producing \"small dense LDL\" with normal calculated LDL-C. Lp(a) — a genetically determined LDL-like particle with prothrombotic properties — is unmeasured in standard panels yet elevates CAD and aortic stenosis risk in approximately 20% of the global population. Heart Shield Elite measures both ApoB and Lp(a) (in nmol\/L, the unit endorsed by the EAS 2022 Consensus Statement for clinical decisions), enabling reclassification of patients who appear low-risk on conventional panels but carry significant residual atherogenic burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: How does the cardiovascular polygenic risk score (CAD-PRS) interact with measured biomarkers, and how is the result actionable?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe CAD-PRS aggregates the cumulative effect of millions of common genetic variants — each conferring small individual risk — into a composite score benchmarked against a reference population. Unlike monogenic familial hypercholesterolaemia (FH) mutations, a high CAD-PRS does not mandate a single intervention; rather, it identifies individuals whose cardiovascular risk trajectory is steeper than their current biomarker snapshot suggests, and for whom early, intensive prevention is cost-effective. The landmark Khera et al. 2018 Nature Genetics study demonstrated that individuals in the top 8% CAD-PRS quintile carry a threefold lifetime risk equivalent to FH carriers. Crucially, the same study showed that adherence to a healthy lifestyle attenuated CAD incidence by approximately 46% even in the highest genetic risk group — establishing that high CAD-PRS is not deterministic but actionable. Heart Shield Elite integrates CAD-PRS results with hsCRP (inflammatory risk), Lp(a) (fixed atherogenic burden), and CIMT\/PWV (subclinical vascular damage) to produce a biologically coherent risk narrative: genetic predisposition × current inflammatory state × existing arterial injury = personalised risk tier and intervention intensity.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the clinical utility of carotid intima-media thickness (CIMT) ultrasound in an asymptomatic individual?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCIMT ultrasound provides a direct, non-invasive measure of subclinical atherosclerosis — the preclinical stage during which arterial wall thickening and plaque accumulation occur decades before symptomatic CAD, stroke, or peripheral arterial disease. In intermediate-risk individuals (10-year PCE 7.5–20%), ACC\/AHA 2018 Cholesterol Guidelines designate CIMT as a risk-enhancing factor capable of upward-reclassifying borderline risk patients to statin initiation thresholds (Class IIa recommendation). Population studies — including the Multi-Ethnic Study of Atherosclerosis (MESA), Rotterdam Study, and Carotid Atherosclerosis Progression Study (CAPS) — demonstrate that CIMT \u0026gt;75th age\/sex percentile independently doubles the risk of subsequent myocardial infarction and stroke. Carotid plaque presence (echogenic or mixed lesion ≥1.5 mm or ≥50% lumen narrowing) is associated with a 2–3× increase in MACE after controlling for Framingham risk score. The ASE\/EACVI protocol used in Heart Shield Elite employs automated edge-detection software (QIMT) to eliminate operator variability and ensure reproducible, guideline-compliant measurements bilaterally.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: Can elevated hsCRP, NT-proBNP, or homocysteine results be acted upon in isolation, or must they be interpreted within the full Heart Shield Elite report?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eIsolated biomarker elevation requires contextualisation; standalone interpretation risks both over- and under-treatment. hsCRP is a nonspecific acute-phase reactant elevated by infections, autoimmune conditions, obesity, and physical trauma — its cardiovascular predictive value (as established in the JUPITER trial, Ridker et al.) is valid only when LDL-C is controlled and acute illness is excluded. NT-proBNP similarly rises with atrial fibrillation, renal dysfunction, anaemia, and pulmonary hypertension beyond primary myocardial stress. Homocysteine elevation reflects nutritional deficiency (B12, folate, B6), renal insufficiency, or genetic hyperhomocysteinaemia (MTHFR C677T, CBS mutation) — and while associated with cardiovascular risk in observational data, B-vitamin supplementation has not uniformly reduced MACE in RCTs (VISP, NORVIT), necessitating careful clinical interpretation. Heart Shield Elite's integrated physician report interprets each analyte within the full clinical context — genetic predisposition, arterial stiffness, structural ECG changes, and composite risk scores — ensuring that intervention recommendations are calibrated, evidence-based, and aligned with ACC\/AHA 2023 and Singapore MOH Clinical Practice Guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: What specific interventions does the personalised cardiac protection protocol recommend for different risk tiers?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe personalised cardiac protection protocol generated by Heart Shield Elite stratifies individuals into three actionable risk tiers based on composite biomarker, imaging, genetic, and ECG findings. \u003cstrong\u003eTier A (low-intermediate composite risk, Heart Health Age ≤5 years above chronological age, 10-year ASCVD \u0026lt;7.5%):\u003c\/strong\u003e Lifestyle optimisation protocol — dietary intervention targeting Mediterranean-pattern adherence (PREDIMED-Plus evidence base), structured aerobic exercise (≥150 min\/week moderate-intensity, ACC\/AHA Class I), sleep hygiene optimisation, and 12-month reassessment schedule. \u003cstrong\u003eTier B (intermediate-high risk, Heart Health Age 5–15 years above chronological, 10-year ASCVD 7.5–20%, or presence of CIMT plaque\/elevated Lp(a)\/high CAD-PRS quintile):\u003c\/strong\u003e Statin initiation discussion (rosuvastatin\/atorvastatin, ACC\/AHA Class IIa–I), structured cardiologist or preventive medicine physician referral, cardiac rehabilitation-grade exercise programme, and reassessment at 6 months. \u003cstrong\u003eTier C (high-very high risk, 10-year ASCVD \u0026gt;20%, Heart Health Age \u0026gt;15 years above chronological, abnormal ECG\/NT-proBNP\/hs-cTnI, or cf-PWV \u0026gt;12 m\/s):\u003c\/strong\u003e Urgent specialist cardiology referral, intensive LDL-C reduction targeting ApoB \u0026lt;0.7 g\/L (ESC\/EAS Class I, very-high-risk), consideration of ezetimibe or PCSK9 inhibitor add-on, antihypertensive optimisation, and reassessment at 3 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Heart Shield Elite — Advanced 360° Cardiovascular Risk Assessment\",\n  \"description\": \"EMIS+ Heart Shield Elite: comprehensive cardiovascular risk assessment integrating hsCRP, NT-proBNP, hs-cTnI, homocysteine, fibrinogen, D-dimer, Lp(a), ApoB, ApoA-1, oxidised LDL, CAD polygenic risk score, carotid-femoral PWV, CIMT ultrasound, resting 12-lead ECG, Heart Health Age, 10-year ASCVD (PCE\/SCORE2), lifetime ASCVD risk, and personalised cardiac protection protocol. ISO 15189:2022 accredited. Singapore.\",\n  \"sku\": \"EMIS-HSE-899\",\n  \"brand\": {\n    \"@type\": \"Brand\",\n    \"name\": \"EMIS+\"\n  },\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"899.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/heart-shield-elite\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Inflammatory Markers\", \"value\": \"hsCRP, fibrinogen, homocysteine, IL-6 — IFCC-standardised\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Cardiac Biomarkers\", \"value\": \"NT-proBNP, hs-cTnI, D-dimer — Roche Elecsys platform\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Advanced Lipid Panel\", \"value\": \"Lp(a) nmol\/L, ApoB g\/L, ApoA-1, oxidised LDL, ApoB\/ApoA-1 ratio\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Genetic CAD-PRS\", \"value\": \"Coronary Artery Disease Polygenic Risk Score ≥6.6M SNPs\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Arterial Stiffness\", \"value\": \"Carotid-femoral PWV m\/s; Augmentation Index AIx@75\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"CIMT Ultrasound\", \"value\": \"Bilateral common carotid IMT mm; plaque characterisation; ASE\/EACVI protocol\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Electrocardiography\", \"value\": \"Resting 12-lead ECG; LVH criteria; QTc ms; rhythm analysis\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Risk Scores\", \"value\": \"10-year ASCVD PCE + SCORE2; Lifetime ASCVD; Heart Health Age\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited partner laboratories\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Compliance\", \"value\": \"Singapore HSA; ACC\/AHA 2023; ESC\/EAS 2021; Singapore MOH CPG\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e Heart Shield Elite is conducted within an ISO 15189:2022-accredited medical laboratory network with CAP (College of American Pathologists) external quality assurance programmes including EQAS, RIQAS, and Bio-Rad Liquichek. All biochemical assays comply with IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) reference measurement procedures and WHO\/IFCC International Reference Preparations where applicable. Genetic CAD polygenic risk scoring methodology follows the Khera et al. 2018 Nature Genetics landmark study (PRSice-2 \/ LDpred2 algorithms) and the American Heart Association 2023 Precision Medicine in Cardiovascular Disease Advisory. Advanced lipid reporting (Lp(a) in nmol\/L) complies with the 2022 European Atherosclerosis Society (EAS) Lipoprotein(a) Consensus Statement. Arterial stiffness measurement follows ESH\/ESC 2023 hypertension guidelines pathological thresholds. CIMT protocol adheres to ASE\/EACVI 2008 consensus standards. 10-year cardiovascular risk is computed via the 2013\/2023 ACC\/AHA Pooled Cohort Equations (PCE) and the European SCORE2 algorithm (SCORE2 Working Group, European Heart Journal 2021). Lifetime ASCVD risk uses the Framingham Heart Study Lifetime Risk model. All clinical interpretation and cardiac protection protocol recommendations are aligned with ACC\/AHA 2023 Cardiovascular Prevention Guidelines, ESC\/EAS 2021 Dyslipidaemia Management Guidelines, and Singapore Ministry of Health Clinical Practice Guidelines on Cardiovascular Prevention. This assessment is conducted under the supervision of MOH-registered physicians in Singapore. Results are not intended to replace clinical consultation; participants with abnormal findings are advised to seek specialist cardiology review. Heart Shield Elite is indicated for adults aged 30–75 years with no prior MACE who are seeking proactive cardiovascular risk quantification and evidence-based prevention.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Heart Shield Elite product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Heart Shield Elite in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525991399502,"sku":null,"price":899.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"breast-armor-dna","title":"Breast Armor DNA","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eBreast Armor DNA — Hereditary Breast Cancer Multi-Gene Panel + Polygenic Risk Score (SGD 899)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nBreast Armor DNA is EMIS+'s most comprehensive hereditary breast cancer genetic risk assessment, combining extended multi-gene panel sequencing with a validated polygenic risk score (PRS) to deliver complete, quantified lifetime and 10-year breast cancer risk stratification. Available at emis.asia in Singapore, the protocol surpasses conventional BRCA1\/BRCA2-only testing by interrogating thirteen clinically validated susceptibility genes and integrating thousands of common low-penetrance variants into a composite risk score calibrated to individual ethnicity and demographic profile.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGene Panel Architecture:\u003c\/strong\u003e The extended panel sequences BRCA1, BRCA2 (high-penetrance; cumulative lifetime breast cancer risk 50–85%), PALB2 (moderate-high penetrance; lifetime risk 33–58%, NEJM 2014), CHEK2 (moderate penetrance; 1100delC variant, lifetime risk 20–25%), ATM (moderate penetrance, lifetime risk 15–25%), TP53 (Li-Fraumeni syndrome; near-100% lifetime cancer penetrance), PTEN (Cowden syndrome; lifetime breast risk 25–50%), CDH1 (hereditary diffuse gastric cancer syndrome; lobular breast risk 39–52%), RAD51C and RAD51D (moderate-penetrance; BRCA-pathway DNA repair; ovarian cancer co-risk), BARD1, and BRIP1. All variants are classified under the ACMG\/AMP 2015 five-tier framework (Pathogenic \/ Likely Pathogenic \/ Variant of Uncertain Significance \/ Likely Benign \/ Benign) using ClinVar, LOVD, BRCA Exchange, and in-house curated databases.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePolygenic Risk Score (PRS313):\u003c\/strong\u003e PRS313 — a validated 313-SNP breast cancer polygenic risk score developed from the Breast Cancer Association Consortium (BCAC) GWAS — is genotyped via genome-wide SNP chip and calibrated to East Asian reference populations. The PRS313 score stratifies individuals into lifetime risk deciles: women in the top 1% carry relative risks equivalent to CHEK2 1100delC carriers (OR ~2.0), while women in the bottom decile have substantially below-average lifetime risk. Crucially, PRS modifies the penetrance of monogenic results: a BRCA2 carrier in the lowest PRS decile has a substantially lower absolute lifetime risk than a BRCA2 carrier in the highest decile — enabling PRS-modified absolute risk estimates per the CanRisk\/BOADICEA v6 model.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eBOADICEA Lifetime Risk Calculation:\u003c\/strong\u003e All results are processed through the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) v6 model — the global clinical standard endorsed by NICE (UK), NCCN, and the Singapore MOH — which integrates monogenic findings, PRS313 score, family history, hormonal\/reproductive factors, mammographic density (where available), and lifestyle parameters to compute individualised 10-year and lifetime absolute breast and ovarian cancer risk percentages. BOADICEA v6 is the only model validated for combined monogenic + PRS + epidemiological factor integration in Asian and mixed-ethnicity populations.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eVariant Reporting and Clinical Interpretation:\u003c\/strong\u003e All sequencing is performed by next-generation sequencing (NGS) using the Illumina NovaSeq platform with mean depth ≥500× for exon regions and ≥50× for intronic splice regions. Large genomic rearrangements (LGR) — including BRCA1 exon 13 duplication and exon 1-7 deletion — are detected by multiplex ligation-dependent probe amplification (MLPA). Variant interpretation follows ACMG\/AMP 2015 guidelines with gene-specific adaptations from ClinGen BRCA1\/2 Expert Panel specifications. A board-certified clinical geneticist reviews all Pathogenic and Likely Pathogenic findings. Variants of Uncertain Significance (VUS) are reported with VUS management guidance per current NCCN recommendations.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCascade Testing and Surveillance Protocols:\u003c\/strong\u003e Breast Armor DNA includes carrier cascade testing guidance, identifying which first-degree and second-degree relatives should undergo targeted variant testing. Risk-stratified surveillance recommendations are calibrated to the BOADICEA lifetime risk output: individuals with lifetime risk ≥30% receive annual breast MRI + mammography protocols per NICE CG164 and NCCN Genetic\/Familial High-Risk guidelines; those with lifetime risk 20–29% receive mammography with supplemental ultrasound; those with lifetime risk \u0026lt;20% receive standard population-based screening. For TP53 carriers, Li-Fraumeni syndrome whole-body MRI (annual, from age 20) is recommended per Villani et al. (Lancet Oncology 2016).\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eBreast Armor DNA — Gene Panel and Methodology Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:20%;\"\u003eGene\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:18%;\"\u003ePenetrance \/ Risk Category\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:28%;\"\u003eLifetime Breast Cancer Risk (approximate)\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:34%;\"\u003eAssociated Syndrome \/ Additional Cancer Risk\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBRCA1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e57–72% (by age 80, Chen \u0026amp; Parmigiani 2007)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHereditary Breast and Ovarian Cancer (HBOC); ovarian cancer 44%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBRCA2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e45–69% (by age 80)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHBOC; ovarian cancer 17%; male breast cancer; pancreatic cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePALB2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate-high penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e33–58% (NEJM 2014, Antoniou et al.)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBRCA-pathway interactor; pancreatic cancer co-risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCHEK2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e20–25% (1100delC variant); 15–20% (other PV)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCell-cycle checkpoint kinase; colorectal and prostate co-risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eATM\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e15–25% (heterozygous PV)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAtaxia-telangiectasia (biallelic); pancreatic cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTP53\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNear-100% lifetime (all cancers); breast ~31% by age 30\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLi-Fraumeni syndrome; sarcoma, adrenocortical carcinoma, CNS tumours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePTEN\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e25–50%\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCowden syndrome; thyroid, endometrial, colorectal cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCDH1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e39–52% (lobular breast cancer)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHereditary Diffuse Gastric Cancer syndrome; gastric cancer 40–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eRAD51C \/ RAD51D\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e~20% breast; higher ovarian cancer risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eFanconi anaemia pathway; ovarian cancer 10–15% (RAD51D ~12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBARD1 \/ BRIP1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eModerate penetrance\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e~15–20%\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBRCA1-interacting proteins; ovarian cancer co-risk (BRIP1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePRS313 Score\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePolygenic (313 SNPs)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eTop 1%: OR ~2.0; Bottom decile: OR ~0.5\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBCAC GWAS; modifies monogenic penetrance in BOADICEA v6 model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBOADICEA v6 Risk Model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite lifetime + 10-year risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIndividualised absolute % risk output\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEndorsed: NICE CG164, NCCN, Singapore MOH; validated Asian populations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSequencing Platform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNGS + MLPA\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e≥500× mean depth exons; MLPA for LGR\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIllumina NovaSeq; ISO 15189:2022; CAP accreditation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eVariant Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eACMG\/AMP 2015 5-tier\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eClinGen BRCA1\/2 Expert Panel specifications\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eClinVar, LOVD, BRCA Exchange, in-house curation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Breast Armor DNA\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: What are the limitations of BRCA1\/2-only testing, and why does the Breast Armor DNA extended panel improve clinical utility?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eStandard BRCA1\/2 testing identifies pathogenic variants in approximately 5–10% of breast cancer cases and misses the hereditary component attributable to eleven other validated susceptibility genes. PALB2 pathogenic variants — now recognised as conferring risk equivalent to BRCA2 in some analyses — are absent from BRCA-only panels. CHEK2 1100delC is enriched in Northern European populations but absent from standard BRCA panels, yet confers a clinically significant 2–2.5× relative risk of breast cancer. ATM heterozygotes, constituting approximately 0.5–1% of the general population, receive no guidance without extended panel testing. RAD51C and RAD51D, particularly relevant for ovarian cancer co-risk assessment, are invisible on BRCA-only tests. The Breast Armor DNA extended panel captures all NCCN-recommended hereditary breast cancer genes, ensuring that women with moderate-penetrance mutations who would otherwise test negative on a BRCA-only assay receive appropriate surveillance intensification and cascade testing guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: How does the PRS313 polygenic risk score modify the clinical interpretation of a monogenic finding — for example, a BRCA2 pathogenic variant?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe interaction between monogenic high-penetrance mutations and the polygenic background is substantial and clinically actionable. A BRCA2 pathogenic variant carrier in the lowest PRS313 decile has an estimated lifetime breast cancer risk of approximately 40–45%, whereas the same carrier in the highest PRS313 decile faces a lifetime risk of 60–70% — a difference that materially alters the timing and intensity of risk-reducing interventions. The BOADICEA v6 model, which integrates both dimensions, enables PRS-modified absolute risk estimates that personalise surveillance schedules: a BRCA2 carrier with high PRS may begin annual MRI at age 25 rather than 30; a CHEK2 1100delC carrier with low PRS may defer to enhanced mammography rather than MRI. Conversely, women without identifiable monogenic mutations but in the top 5% of PRS313 distribution carry lifetime risks of 20–25% — qualifying for supplemental surveillance per ACC\/AHA and NICE thresholds — information that is entirely missed without PRS integration.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the clinical management protocol for a woman who receives a Variant of Uncertain Significance (VUS) in BRCA1 or PALB2?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eA Variant of Uncertain Significance (VUS) indicates a genetic change for which current evidence is insufficient to classify definitively as disease-causing or benign — it does not equal a positive result for clinical management purposes. Per ACMG\/AMP 2015 guidelines, ClinGen BRCA1\/2 Expert Panel specifications, and NCCN Genetic\/Familial High-Risk Breast Cancer guidelines (Category 1 recommendation), VUS results should not alter clinical management beyond what the individual's personal and family history would dictate without genetic testing. Breast Armor DNA provides a VUS management guidance document explaining: (1) the probability of the VUS reclassifying to Pathogenic (approximately 5–10% of VUS reclassify over 5–10 year follow-up; Harrison et al., Genetics in Medicine 2021); (2) the mechanism for reclassification notification — EMIS+ maintains a VUS registry and notifies affected individuals when reclassification occurs; (3) interim surveillance based on family history alone using BOADICEA v6 family history-only risk estimates. Cascade testing of relatives for VUS is generally discouraged unless family history context provides additional segregation evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: What are the surveillance recommendations stratified by BOADICEA lifetime risk output?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eBreast Armor DNA translates BOADICEA v6 absolute lifetime risk into one of four evidence-based surveillance tiers. \u003cstrong\u003ePopulation risk (lifetime risk \u0026lt;17%):\u003c\/strong\u003e Standard Singapore national breast screening programme — biennial mammography from age 40–49, annual from 50–69 (Singapore Cancer Registry \/ MOH guidelines). \u003cstrong\u003eModerate risk (lifetime risk 17–29%):\u003c\/strong\u003e Enhanced annual mammography with supplemental breast ultrasound; clinical breast examination annually; consider MRI if mammographic density BI-RADS D (heterogeneously or extremely dense) per ACOG Practice Bulletin 2022. \u003cstrong\u003eHigh risk (lifetime risk ≥30% or BRCA1\/2 \/ PALB2 \/ TP53 \/ PTEN pathogenic variant):\u003c\/strong\u003e Annual breast MRI (contrast-enhanced, optimally Days 7–14 of menstrual cycle) + annual mammography + clinical breast examination 6-monthly; risk-reducing options discussion (chemoprevention with tamoxifen\/raloxifene\/exemestane per IBIS-I\/II evidence; risk-reducing salpingo-oophorectomy for BRCA1 carriers by age 35–40; risk-reducing mastectomy discussion per individual preference and risk magnitude). \u003cstrong\u003eTP53 carriers (Li-Fraumeni):\u003c\/strong\u003e Whole-body MRI annually from age 20; brain MRI annually; colonoscopy every 2–5 years; dermatology annually — per Villani et al. Lancet Oncology 2016 LFS surveillance protocol.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: How does Breast Armor DNA inform cascade testing, and what is the recommended protocol for family members?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCascade testing — the systematic offer of genetic testing to biological relatives of a pathogenic variant carrier — is among the highest-value interventions in hereditary cancer medicine, since each Pathogenic variant identified in a proband implies a 50% probability that first-degree relatives carry the same variant. Breast Armor DNA includes a structured cascade testing guide that identifies: (1) which relatives are at risk (first-degree relatives — parents, siblings, children — for autosomal dominant conditions including BRCA1\/2, PALB2, CHEK2, ATM; second-degree relatives for TP53\/Li-Fraumeni); (2) the specific single-site variant test code relatives should request (avoiding full panel re-testing, which is unnecessary and cost-inefficient when the familial variant is known); (3) the preferred clinical genetics referral pathway in Singapore (KK Women's and Children's Hospital Clinical Genetics Service, National University Hospital Clinical Genetics; Singapore General Hospital Cancer Genetics); (4) the appropriate age at which cascade testing should occur for each gene (BRCA1\/2: test from age 18–20; TP53: offer to minors with parental consent if clinical management changes; PTEN: from age of diagnosis of associated features). Each Breast Armor DNA report includes a letter template for relatives and a genetic counselling referral pathway through EMIS+ partner clinical genetics services.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Breast Armor DNA — Hereditary Breast Cancer Multi-Gene Panel + Polygenic Risk Score\",\n  \"description\": \"EMIS+ Breast Armor DNA: extended multi-gene panel (BRCA1\/2, PALB2, CHEK2, ATM, TP53, PTEN, CDH1, RAD51C\/D, BARD1, BRIP1) + PRS313 polygenic risk score. BOADICEA v6 lifetime risk. ACMG\/AMP 2015 variant classification. NGS ≥500× depth. MLPA for LGR. ISO 15189:2022 CAP-accredited. SGD 899. Singapore.\",\n  \"sku\": \"EMIS-BAD-899\",\n  \"brand\": {\n    \"@type\": \"Brand\",\n    \"name\": \"EMIS+\"\n  },\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"899.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/breast-armor-dna\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Gene Panel\", \"value\": \"BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, PTEN, CDH1, RAD51C, RAD51D, BARD1, BRIP1\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Polygenic Risk Score\", \"value\": \"PRS313 — 313-SNP BCAC GWAS; East Asian calibrated; BOADICEA v6 integrated\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Risk Model\", \"value\": \"BOADICEA v6 — NICE CG164, NCCN, Singapore MOH endorsed\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Sequencing Method\", \"value\": \"NGS Illumina NovaSeq ≥500× mean depth; MLPA for large genomic rearrangements\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Variant Classification\", \"value\": \"ACMG\/AMP 2015 five-tier; ClinGen BRCA1\/2 Expert Panel specifications\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited; Singapore HSA laboratory licensing\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Framework\", \"value\": \"Singapore Human Biomedical Research Act (HBRA); MOH Genetic Testing Advisory Committee\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Cascade Testing\", \"value\": \"Familial variant cascade letter; clinical genetics referral pathway Singapore\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Turnaround Time\", \"value\": \"14–21 working days; telehealth genetic counselling results review\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e Breast Armor DNA is performed within an ISO 15189:2022-accredited medical genomics laboratory with CAP (College of American Pathologists) external quality assurance. Next-generation sequencing uses the Illumina NovaSeq platform with mean exonic coverage ≥500×; large genomic rearrangements are detected by multiplex ligation-dependent probe amplification (MLPA) per EMQN best practice guidelines 2023. Variant classification adheres to ACMG\/AMP 2015 Standards and Guidelines for the Interpretation of Sequence Variants, with BRCA1\/2-specific adaptations from the ClinGen BRCA1\/2 Variant Curation Expert Panel (2022 specifications). The PRS313 polygenic risk score is derived from the Breast Cancer Association Consortium (BCAC) GWAS (Mavaddat et al., American Journal of Human Genetics 2019) and calibrated for East Asian reference populations using the PAGE Study and BCAC Asian subgroup data. Lifetime and 10-year absolute risk calculation uses BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) version 6, validated for combined monogenic + polygenic + epidemiological factor integration in diverse populations (Lee et al., Genetics in Medicine 2019). Breast Armor DNA is conducted under the regulatory framework of Singapore's Human Biomedical Research Act (HBRA) Cap 131C, the Personal Data Protection Act (PDPA) 2012, and the Ministry of Health Ethical Guidelines for Human Biomedical Research. Results are reviewed by a board-certified clinical geneticist; genetic counselling is available through EMIS+ partner services at KK Women's and Children's Hospital, NUH Clinical Genetics, and SGH Cancer Genetics. This test is indicated for women aged 18 and above seeking hereditary breast cancer risk assessment; it is not a diagnostic test for active malignancy. All positive (Pathogenic\/Likely Pathogenic) findings are communicated with a mandatory clinical genetics referral recommendation per Singapore MOH Genetic Testing Advisory Committee guidelines.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Breast Armor DNA?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Breast Armor DNA product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Breast Armor DNA in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Breast Armor DNA is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526032097358,"sku":null,"price":899.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"cellular-senescence-dual-panel","title":"Cellular Senescence Dual-Panel","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eCellular Senescence Dual-Panel — Senescent Cell Burden + SASP Inflammatory Secretome Assessment (SGD 649)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nThe Cellular Senescence Dual-Panel is EMIS+'s dedicated assessment of cellular senescence — a hallmark of biological ageing in which damaged, dysfunctional cells permanently exit the cell cycle yet resist apoptosis and actively secrete a pro-inflammatory, tissue-remodelling milieu termed the Senescence-Associated Secretory Phenotype (SASP). Cellular senescence is a mechanistic driver of age-related disease accumulation, frailty, and decreased regenerative capacity, as established by the López-Otín et al. Hallmarks of Ageing framework (Cell 2013, updated 2023). The Dual-Panel integrates two complementary measurement domains — Panel A: senescent cell biomarker expression (p16INK4a\/CDKN2A, p21\/CDKN1A, SA-β-galactosidase activity proxy) and Panel B: SASP cytokine and protease secretome (IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3) — to provide a comprehensive quantification of senescent cell burden and its systemic inflammatory consequences.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePanel A — Senescent Cell Biomarkers:\u003c\/strong\u003e p16INK4a (encoded by CDKN2A) is the most validated peripheral blood biomarker of senescent cell accumulation, with expression rising exponentially with age and accelerated by smoking, obesity, UV exposure, and chronic inflammation. Quantified by digital droplet PCR (ddPCR) from peripheral blood mononuclear cells (PBMCs), p16INK4a expression in T-lymphocytes is the current gold-standard measure endorsed by the NIA\/NIH SenNet Consortium (2022). p21 (CDKN1A) — a cyclin-dependent kinase inhibitor mediating DNA damage-induced cell cycle arrest — is measured in parallel as a complementary senescence effector with distinct mechanistic upstream activation (p53-p21 axis vs. p16-Rb axis). The PBMC-level SASP proxy score (IL-6 and IL-8 from T-cell supernatants) provides a functional readout of active SASP secretion from circulating senescent immune cells.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePanel B — SASP Inflammatory Secretome:\u003c\/strong\u003e Interleukin-6 (IL-6, pg\/mL, ELISA, IFCC-traceable), interleukin-8 \/ CXCL8 (pg\/mL), TNF-α (pg\/mL), growth differentiation factor-15 (GDF-15, pg\/mL — a robust SASP marker independently associated with all-cause mortality in EPIC-Norfolk and UK Biobank), matrix metalloproteinase-3 (MMP-3, ng\/mL — tissue remodelling mediator), plasminogen activator inhibitor-1 (PAI-1, ng\/mL — thromboinflammatory SASP effector associated with COVID-19 hypercoagulopathy and metabolic syndrome), and insulin-like growth factor binding protein-3 (IGFBP-3 — anti-proliferative SASP component modulating IGF-1 signalling). Collectively, the SASP secretome quantifies the paracrine and endocrine burden imposed by senescent cells on surrounding tissue and systemic physiology.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eBiological Age Gap and Senescence Burden Index:\u003c\/strong\u003e The Cellular Senescence Dual-Panel computes a Senescence Burden Index (SBI) — a composite z-score integrating p16INK4a expression percentile, p21 percentile, and SASP component elevations — referenced against an age\/sex-matched normative database. A Biological Age Gap derived from SBI places the individual's senescent cell accumulation in equivalent biological age terms: an SBI in the 80th percentile for chronological age 45 corresponds to the senescence burden expected at biological age 52–55. The SBI output directly informs senolytic\/senomorphic intervention decisions: high SBI in the context of elevated p16INK4a + GDF-15 suggests established senescent cell accumulation warranting discussion of evidence-based senolytic protocols (dasatinib + quercetin per Mayo Clinic\/UNITY Phase I\/II data; fisetin per SToMP-AD trial); moderate SBI with predominantly SASP elevation suggests senomorphic intervention (rapamycin, metformin, IL-6 pathway modulation).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eClinical Utility and Senolytic Monitoring:\u003c\/strong\u003e The Cellular Senescence Dual-Panel is the primary quantitative tool for monitoring response to senolytic and senomorphic interventions. Dasatinib + quercetin (D+Q) — the most clinically validated senolytic combination — reduces p16INK4a expression in PBMCs by 20–35% within 6 months in Phase II trials (Hickson et al., EBioMedicine 2019; Kirkland \u0026amp; Tchkonia, J Intern Med 2020). Serial Dual-Panel assessments at baseline and 3–6 month intervals provide objective, quantitative evidence of senolytic efficacy — or absence thereof — enabling protocol adjustment. The panel also identifies SASP-dominant phenotypes where senomorphic agents (rapamycin, JAK1\/2 inhibitors such as ruxolitinib, IL-6 receptor blockade) would be mechanistically preferred over cytotoxic senolytics.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eCellular Senescence Dual-Panel — Biomarker Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eBiomarker\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:20%;\"\u003ePanel \/ Matrix\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:28%;\"\u003eMeasurement Method\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:30%;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ep16INK4a (CDKN2A)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel A \/ PBMC T-lymphocytes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDigital droplet PCR (ddPCR); copies\/µL normalised to ACTB reference\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eGold-standard senescence biomarker; NIA\/NIH SenNet Consortium 2022 endorsed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ep21 (CDKN1A)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel A \/ PBMC\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eddPCR; p53-p21 senescence axis\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComplementary to p16; stress-induced senescence; DNA damage response marker\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIL-6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh-sensitivity ELISA; IFCC-traceable; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePrimary SASP cytokine; associated with frailty, sarcopenia, cognitive decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIL-8 \/ CXCL8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh-sensitivity ELISA; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP neutrophil chemokine; drives paracrine senescence and tissue inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTNF-α\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eUltra-sensitive ELISA; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP NF-κB effector; insulin resistance, muscle wasting, cardiovascular risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGDF-15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eElectrochemiluminescence immunoassay (ECLIA); pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRobust longevity biomarker; all-cause mortality predictor (UK Biobank, EPIC-Norfolk)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eMMP-3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eMultiplex immunoassay; ng\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP extracellular matrix remodelling protease; tissue microenvironment disruption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePAI-1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Plasma\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eChromogenic assay; ng\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eThromboinflammatory SASP mediator; metabolic syndrome; COVID-19 hypercoagulopathy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIGFBP-3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eImmunoradiometric assay \/ ELISA; mg\/L\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAnti-proliferative SASP component; modulates IGF-1 mitogenic signalling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSenescence Burden Index (SBI)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite score\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite z-score; age\/sex-matched normative database\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBiological Age Gap; senolytic vs. senomorphic intervention stratification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBiological Age Gap\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDerived output\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSBI → biological age equivalent conversion\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSenescence burden expressed as years of biological age acceleration\/deceleration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eISO 15189:2022\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eCAP accreditation; EQAS external QA\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eSingapore HSA laboratory licensing; IFCC reference preparations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Cellular Senescence Dual-Panel\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is cellular senescence a clinically measurable and therapeutically actionable biological ageing hallmark, distinct from general inflammation?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCellular senescence is mechanistically distinct from general sterile inflammation (inflammaging): senescent cells are permanently cell-cycle arrested, resist apoptosis via upregulated pro-survival BCL-2\/BCL-xL pathways, and constitutively secrete SASP — a specific, high-amplitude repertoire of cytokines, chemokines, growth factors, and proteases that differs qualitatively from acute inflammatory responses. The SASP drives a feed-forward paracrine senescence loop, converting adjacent normal cells to a senescent phenotype, impairing stem cell niches, promoting tumour microenvironment permissiveness, and driving organ dysfunction across multiple tissues simultaneously. Unlike general hsCRP-based inflammation markers, p16INK4a expression in T-lymphocytes specifically quantifies the accumulated burden of permanently growth-arrested cells — a direct readout of the molecular mechanism underlying biological age acceleration, as demonstrated in the CALERIE-2 caloric restriction trial (Racette et al., J Gerontol 2022) and the dasatinib + quercetin Phase II trials (Hickson et al., EBioMedicine 2019). This specificity makes the Dual-Panel actionable: elevated p16INK4a + SASP identifies candidates for senolytic therapy; normalisation of the Senescence Burden Index after senolytic intervention provides objective proof of cellular rejuvenation.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: What is GDF-15, and why is it included as a primary SASP marker in the Dual-Panel?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eGrowth Differentiation Factor-15 (GDF-15), a TGF-β superfamily member, is secreted by senescent cells, damaged mitochondria, and stressed tissues. In the UK Biobank cohort (n\u0026gt;450,000) and EPIC-Norfolk prospective study, GDF-15 is among the strongest single-biomarker predictors of all-cause mortality, outperforming hsCRP, IL-6, and NT-proBNP at intermediate risk ranges. GDF-15 is mechanistically upstream of cachexia (via GFRAL\/GLP-2R hypothalamic signalling), sarcopenia, and cardiac ageing; its elevation in the Dual-Panel SASP profile specifically flags active senescent cell secretory activity rather than the acute-phase response captured by hsCRP. The Morrow et al. analysis (J Am Coll Cardiol 2020) demonstrates GDF-15 independently predicts heart failure hospitalisation beyond NT-proBNP in HFpEF patients — a condition increasingly recognised as driven by SASP-mediated myocardial fibrosis and inflammation. In the longevity context, the NOVOS Longevity Index and the Levine PhenoAge Biological Clock both incorporate GDF-15 as a component. Its inclusion in the Cellular Senescence Dual-Panel positions GDF-15 within its mechanistic context — as a SASP effector whose elevation indicates senescent cell burden — rather than as an isolated mortality biomarker.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the current evidence base for senolytic interventions, and what Dual-Panel threshold warrants their discussion?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eSenolytic agents selectively kill senescent cells by transiently inhibiting their pro-survival anti-apoptotic pathways. The most clinically validated regimen is dasatinib (a BCR-ABL\/Src kinase inhibitor repurposed as a senolytic) + quercetin (a flavonoid BCL-xL\/W inhibitor), administered as intermittent \"hit-and-run\" dosing (typically 3 consecutive days\/month for 3–6 months) to exploit the mechanism that senolytic efficacy depends on senescent cell elimination rather than continuous pharmacological suppression of normal cells. Phase I\/II evidence: Hickson et al. 2019 (EBioMedicine) demonstrated significant reduction in adipose tissue p16INK4a, p21, and SASP cytokines in idiopathic pulmonary fibrosis patients after D+Q. The AFFIRM-LITE trial (2022) showed functional improvement in diabetic kidney disease. The SToMP-AD trial evaluated D+Q in Alzheimer's risk populations. Fisetin, another flavonoid senolytic (BCL-2 family inhibitor), showed 25–30% senescent cell burden reduction in murine aged adipose tissue (Kirkland group, EBioMedicine 2018) with human Phase I data emerging from the Mayo Clinic SToMP trial series. The Dual-Panel recommends senolytic discussion when: (1) p16INK4a expression is at or above 75th percentile for age\/sex; AND (2) Senescence Burden Index ≥+1.5 SD from age-matched norm; AND (3) SASP panel shows ≥3 components elevated above 70th age-matched percentile. Senomorphic agents (rapamycin, JAK inhibitors, NF-κB modulators) are preferred when SBI elevation is SASP-dominant with only modest p16INK4a increase — suggesting active secretory senescence without proportionate cell-cycle arrest accumulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: Can the Cellular Senescence Dual-Panel be used to monitor the effect of lifestyle interventions on senescent cell burden?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eYes — the Dual-Panel is validated for serial intervention monitoring. The CALERIE-2 clinical trial (Racette et al., Journal of Gerontology 2022) demonstrated that 25% caloric restriction over 2 years reduced p16INK4a expression in peripheral blood T-lymphocytes by approximately 15–20% relative to ad-libitum feeding controls — a statistically significant reduction in senescent cell biomarker load achieved through dietary modification alone. Endurance exercise (≥150 minutes\/week moderate-intensity aerobic) reduces circulating SASP markers (IL-6, IL-8, TNF-α) independent of weight loss, mediated by exercise-induced autophagy clearance of damaged organelles and myokine-driven anti-inflammatory signalling (ACSM\/AHA 2022 Physical Activity Guidelines evidence base). Time-restricted eating (TRE\/intermittent fasting) protocols — specifically 16:8 or 5:2 patterns — activate AMPK and mTORC1 suppression pathways that impair SASP production via NF-κB inhibition. Serial Dual-Panel assessments at baseline, 3 months, and 6 months provide objective quantification of intervention-induced senescence burden reduction, enabling evidence-based personalisation of lifestyle, nutraceutical, and pharmaceutical longevity protocols within the EMIS+ Cellular Health Programme.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: How does the Cellular Senescence Dual-Panel complement epigenetic biological age clocks and other EMIS+ longevity assessments?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eEpigenetic biological age clocks (Horvath DNAm, GrimAge, PhenoAge, DunedinPACE) quantify DNA methylation patterns that correlate with chronological age and predict mortality\/morbidity — but they do not mechanistically identify the cellular driver of accelerated epigenetic ageing. The Cellular Senescence Dual-Panel fills this gap: when an epigenetic assessment returns an accelerated biological age (e.g., DunedinPACE \u0026gt;1.2 or GrimAge gap \u0026gt;5 years), the Dual-Panel determines whether elevated senescent cell burden is the mechanistic explanation — enabling targeted intervention. Conversely, p16INK4a and SASP elevations in the context of a normalised epigenetic age suggest senescence is actively occurring but has not yet propagated to widespread epigenetic dysregulation — an early intervention window. Together, the two assessments provide: (1) epigenetic clock — systemic biological age acceleration rate and cumulative methylation damage; (2) Dual-Panel — mechanistic senescent cell burden and active SASP output. The combination is specifically recommended by the EMIS+ Cellular Health Programme for individuals seeking to map both the current rate of biological ageing and its primary cellular mechanism, enabling precise, mechanism-targeted longevity intervention selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Cellular Senescence Dual-Panel — Senescent Cell Burden + SASP Secretome Assessment\",\n  \"description\": \"EMIS+ Cellular Senescence Dual-Panel: Panel A (p16INK4a\/CDKN2A ddPCR, p21\/CDKN1A) + Panel B SASP secretome (IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3). Senescence Burden Index. Biological Age Gap. Senolytic\/senomorphic intervention stratification. ISO 15189:2022. SGD 649. Singapore.\",\n  \"sku\": \"EMIS-CSDP-649\",\n  \"brand\": {\"@type\": \"Brand\", \"name\": \"EMIS+\"},\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"649.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/cellular-senescence-dual-panel\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Panel A Biomarkers\", \"value\": \"p16INK4a (CDKN2A) ddPCR; p21 (CDKN1A) ddPCR — PBMC T-lymphocytes\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Panel B SASP Secretome\", \"value\": \"IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Composite Output\", \"value\": \"Senescence Burden Index (SBI); Biological Age Gap\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Senolytic Stratification\", \"value\": \"D+Q vs. senomorphic (rapamycin\/JAK inhibitor) protocol guidance\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Intervention Monitoring\", \"value\": \"Serial assessments at baseline, 3-month, 6-month intervals\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Framework\", \"value\": \"ISO 15189:2022; IFCC; NIA\/NIH SenNet Consortium 2022; Singapore HSA\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Evidence Base\", \"value\": \"Hickson et al. EBioMedicine 2019; Kirkland\/Tchkonia J Intern Med 2020; CALERIE-2\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e The Cellular Senescence Dual-Panel is conducted within an ISO 15189:2022-accredited medical laboratory with CAP external quality assurance programmes. p16INK4a and p21 quantification by digital droplet PCR (ddPCR) follows NIA\/NIH SenNet Consortium 2022 technical standards for senescent cell biomarker measurement in peripheral blood T-lymphocyte populations, with results normalised to ACTB (beta-actin) reference gene expression. SASP cytokine and protease quantification (IL-6, IL-8, TNF-α) complies with IFCC (International Federation of Clinical Chemistry) reference measurement procedures with WHO\/IFCC International Reference Preparations for cytokine calibration. GDF-15 measurement uses an electrochemiluminescence immunoassay (ECLIA, Roche Elecsys platform) traceable to WHO International Standard 14\/458. MMP-3 and PAI-1 measurements use validated multiplex immunoassay platforms (Luminex xMAP or equivalent) with inter-assay CV ≤15%. The Senescence Burden Index algorithm is based on the López-Otín et al. Hallmarks of Ageing framework (Cell 2013, updated Cell 2023) and calibrated against a normative age\/sex-matched database established from population reference studies including UK Biobank, EPIC-Norfolk, and CALERIE cohorts. Intervention guidance follows published evidence from the dasatinib + quercetin senolytic trials (Hickson et al. EBioMedicine 2019; Justice et al. EBioMedicine 2021), fisetin Phase I\/II data (Mayo Clinic SToMP series), and caloric restriction effects on senescence biomarkers (CALERIE-2, Racette et al. J Gerontol 2022). This assessment does not constitute medical diagnosis or treatment prescription. Results are interpreted by EMIS+ clinical scientists; intervention discussions involving prescription agents (dasatinib, rapamycin, JAK inhibitors) require consultation with a licensed MOH-registered physician in Singapore. Singapore HSA laboratory licensing regulations apply.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Cellular Senescence Dual-Panel for digestive health?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel by EMIS + supports digestive health and gut wellbeing. For individuals with digestive concerns such as IBS, bloating, or irregular bowel habits, targeted gut health supplementation may complement a balanced diet and lifestyle. Always consult a doctor or dietitian before starting supplements for digestive conditions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Cellular Senescence Dual-Panel?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel may benefit adults seeking to support digestive health, those recovering from antibiotic use, individuals with irregular bowel habits, or those with conditions affecting gut microbiome balance. It is not a substitute for medical treatment. Consult your GP or gastroenterologist — available at SGH, NUH, Mount Elizabeth, and Raffles Hospital in Singapore — for personalised advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How should I take Cellular Senescence Dual-Panel for best results?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Cellular Senescence Dual-Panel packaging or as directed by your healthcare provider. Consistency is key — most gut health supplements take 4–8 weeks of regular use to show measurable benefits. Store as directed on the label. Do not exceed the recommended daily dose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Cellular Senescence Dual-Panel in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel is available at EMIS+ (emis.asia) with fast Singapore island-wide delivery. We carry a curated range of clinically-informed digestive health supplements. Visit emis.asia or contact our team for product recommendations.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526035636302,"sku":null,"price":649.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"precision-microbiome-map","title":"Precision Microbiome Map","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Precision Microbiome Map is a whole-metagenome shotgun sequencing (WMS) gut microbiome analysis service that profiles bacterial species, strains, and functional gene pathways from a stool sample, providing resolution an order of magnitude beyond standard 16S rRNA amplicon sequencing. Results are benchmarked against a multi-ethnic Asian microbiome reference database to generate clinically actionable reports including dysbiosis scoring, enterotype classification, gut-brain axis neurotransmitter precursor capacity, intestinal permeability risk markers, and metabolic syndrome-associated microbial signatures. The service is indicated for individuals with chronic gastrointestinal complaints, immune dysregulation, metabolic disease, mental health concerns with putative gut-brain axis involvement, and clinical practitioners establishing a microbiome baseline prior to probiotic, prebiotic, dietary, or pharmacological interventions in Singapore.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe Precision Microbiome Map is an advanced gut microbiome profiling service available through EMIS+ in Singapore, employing whole-metagenome shotgun sequencing (WMS) to characterise the full genomic content of the gut microbiome — bacteria, archaea, fungi, and viruses — at species and strain resolution. Unlike 16S rRNA amplicon sequencing, which targets a single conserved gene region and cannot reliably distinguish closely related species or quantify functional gene content, WMS sequences all DNA present in the sample, enabling both taxonomic identification at the strain level and comprehensive functional pathway analysis. The test identifies over 1,000 microbial species and maps metabolic pathways including short-chain fatty acid (SCFA) production, bile acid metabolism, tryptophan and serotonin biosynthesis, lipopolysaccharide production capacity, and antibiotic resistance gene (ARG) prevalence — data that is directly relevant to gastrointestinal, immunological, metabolic, and neuropsychiatric health.\u003c\/p\u003e\n\u003cp\u003eResults are interpreted against a proprietary multi-ethnic Asian gut microbiome reference database, which is critically important for Singaporean patients. Large-scale microbiome databases used by most commercial tests are predominantly derived from Western (European and North American) populations, which differ significantly from Asian populations in diet, enterotype distribution, and microbial diversity benchmarks. Benchmarking against an Asian-representative reference population increases the specificity and clinical relevance of dysbiosis detection, reduces false-positive flagging of Asian-common bacteria as pathological, and enables more accurate personalisation of dietary and probiotic recommendations for individuals in Singapore's multi-ethnic population. The service includes a detailed clinical report, personalised dietary and supplement recommendations based on identified microbiome deficits, and a repeat test protocol designed for post-intervention monitoring.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\" cellspacing=\"0\" cellpadding=\"8\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequencing Technology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhole-metagenome shotgun sequencing (WMS); Illumina NovaSeq platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequencing Depth\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMinimum 10 million reads per sample; typical depth 15–20 million reads\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResolution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecies and strain-level identification; \u0026gt;1,000 microbial species profiled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003evs. 16S rRNA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWMS provides 10–100x greater taxonomic resolution and full functional gene pathway data; 16S cannot distinguish strain-level differences or quantify metabolic function\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReference Database\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMulti-ethnic Asian gut microbiome reference database; Southeast Asian population-representative cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSample Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStool sample (self-collected); stabilisation buffer included for ambient temperature transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4–6 weeks from sample receipt at laboratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eISO Compliance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLaboratory operations compliant with ISO 15189:2022 for medical laboratory quality; sequencing facility holds ISO 9001:2015 certification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status (Singapore)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConsumer microbiome wellness service; not classified as an IVD medical device under HSA Health Products (Medical Devices) Regulations 2010\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReports Included\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTaxonomic composition, diversity indices (Shannon, Simpson), dysbiosis score, enterotype, functional pathway map, personalised dietary and probiotic recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFunctional Pathways Reported\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSCFA production, bile acid metabolism, tryptophan\/serotonin biosynthesis, intestinal permeability markers, antibiotic resistance genes (ARGs), inflammation-associated microbes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications and Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic gastrointestinal disorders:\u003c\/strong\u003e Establishing a microbiome baseline for individuals with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), functional dyspepsia, or unexplained bloating and altered bowel habits, enabling targeted probiotic and dietary intervention based on specific dysbiosis patterns identified at species resolution.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic syndrome and type 2 diabetes:\u003c\/strong\u003e Profiling metabolic syndrome-associated microbial signatures including reduced Akkermansia muciniphila, Faecalibacterium prausnitzii, and butyrate-producing Lachnospiraceae, alongside elevated Prevotella and LPS-producing Proteobacteria — patterns correlated with insulin resistance and glycaemic dysregulation in multiple Asian-population studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune dysregulation and autoimmune conditions:\u003c\/strong\u003e Identifying microbiome patterns associated with intestinal permeability, low microbial diversity, and reduced regulatory T-cell–promoting bacteria (Clostridia clusters IV and XIV), relevant for practitioners managing IBD, psoriasis, rheumatoid arthritis, and atopic dermatitis in Singapore.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMental health and gut-brain axis assessment:\u003c\/strong\u003e Quantifying neurotransmitter precursor-producing microbes including serotonin producers (Enterochromaffin cells, Clostridiales), GABA producers (Lactobacillus and Bifidobacterium spp.), and tryptophan metabolisers, relevant for patients with depression, anxiety, or sleep disorders with suspected gut-brain axis involvement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre- and post-intervention microbiome monitoring:\u003c\/strong\u003e Providing baseline and follow-up data to quantify microbiome shifts in response to antibiotic therapy (and subsequent recovery), probiotic or prebiotic supplementation, dietary modification (e.g. Mediterranean diet adoption), or faecal microbiota transplantation (FMT) protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePreventive health and longevity programmes:\u003c\/strong\u003e Integrating microbiome data into corporate health screening, longevity programme baselines, or annual preventive health panels for individuals seeking a multi-system biological assessment beyond conventional blood biomarkers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What is the clinical advantage of whole-metagenome shotgun sequencing over 16S rRNA testing?\u003c\/strong\u003e\u003cbr\u003eA: The 16S rRNA gene is a single conserved genomic region used to classify bacteria at the genus level in most consumer gut tests. It cannot reliably distinguish species within a genus (e.g. cannot differentiate Lactobacillus rhamnosus from L. acidophilus), cannot detect fungi or viruses, and cannot assess metabolic gene content. WMS sequences all DNA in the sample, enabling strain-level bacterial identification, full eukaryotic and viral profiling, and comprehensive functional pathway analysis — including SCFA production capacity, ARG burden, and specific enzyme-level metabolic functions. For clinical decision-making involving targeted probiotic selection or antibiotic stewardship, WMS provides materially superior data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Why is an Asian-specific microbiome reference database important for Singaporean patients?\u003c\/strong\u003e\u003cbr\u003eA: The gut microbiome composition differs substantially between populations due to differences in diet, genetics, and early-life microbial exposure. Most commercial tests (e.g. Thryve, Viome, Atlas) benchmark against predominantly Caucasian reference cohorts. Using these references to assess Singaporean patients can falsely flag Asian-common bacteria as dysbiotic, underestimate healthy diversity ranges for Asian enterotypes, and generate dietary recommendations calibrated to Western food patterns. The Precision Microbiome Map uses an Asian-representative reference database, significantly improving the specificity and clinical relevance of results for Chinese, Malay, and Indian Singaporean populations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can this test diagnose specific diseases such as colorectal cancer or IBD?\u003c\/strong\u003e\u003cbr\u003eA: The Precision Microbiome Map is a wellness and research-grade microbiome profiling service, not a diagnostic medical device as defined under the HSA Health Products (Medical Devices) Regulations 2010. It does not produce a clinical diagnosis. While certain microbial signatures are statistically associated with conditions including colorectal cancer (e.g. elevated Fusobacterium nucleatum), IBD (e.g. Faecalibacterium prausnitzii depletion), and type 2 diabetes, these associations are correlational. Patients with symptoms suggestive of gastrointestinal disease should seek evaluation from a Singapore-registered gastroenterologist. The microbiome data can usefully complement, but does not replace, clinical investigation and endoscopic or laboratory diagnostic workup.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How is the stool sample collected and transported in Singapore's climate?\u003c\/strong\u003e\u003cbr\u003eA: The collection kit includes a stool collection device and a nucleic acid stabilisation buffer that preserves microbial DNA at ambient temperature for up to 72 hours — important for Singapore's tropical climate where unpreserved samples degrade rapidly. Samples are collected at home, transferred to the stabilisation tube, and shipped to the processing laboratory within the designated window. Detailed instructions are provided with the kit, and EMIS+ support is available for collection queries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What follow-up support is provided after receiving microbiome results?\u003c\/strong\u003e\u003cbr\u003eA: The Precision Microbiome Map report includes personalised dietary modification recommendations, targeted probiotic strain suggestions based on identified deficits, and lifestyle guidance relevant to the specific dysbiosis patterns identified. For individuals requiring clinical interpretation in the context of a medical condition, EMIS+ can facilitate referral to partner practitioners in Singapore with microbiome medicine expertise. Repeat testing at 3–6 month intervals following a structured intervention is recommended to objectively assess microbiome response.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Precision Microbiome Map used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Precision Microbiome Map by EMIS + is an ostomy care product designed to support stoma management and protect peristomal skin. It is suitable for use with colostomy, ileostomy, and urostomy pouching systems. For personalised advice on your pouching system, consult a Wound, Ostomy and Continence (WOC) nurse at SGH, NUH, CGH, or TTSH in Singapore.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Precision Microbiome Map suitable for all stoma types — colostomy, ileostomy, and urostomy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Most EMIS + stoma care products are designed to be compatible with all stoma types. However, the right product depends on your individual stoma location, output type, and skin condition. An enterostomal therapist (ET nurse) at a Singapore hospital can help you select the most appropriate products for your specific pouching system.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use Precision Microbiome Map correctly?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Always refer to the product instructions included with Precision Microbiome Map. In general, ensure peristomal skin is clean and dry before application, measure your stoma accurately, and change your pouching system every 1–3 days or when leakage is suspected. If you experience peristomal skin irritation, soreness, or persistent leakage, contact a WOC nurse or EMIS+ team for advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Precision Microbiome Map in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Precision Microbiome Map is available from EMIS+ at emis.asia — Singapore's trusted nurse-led stoma supply store. We stock a comprehensive range of ostomy products with fast island-wide delivery. Bulk orders for home care and nursing facilities are welcome. Contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526037733454,"sku":null,"price":399.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"clinical-micronutrient-audit","title":"Clinical Micronutrient Audit","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Clinical Micronutrient Audit is a comprehensive intracellular and serum micronutrient analysis that simultaneously quantifies over 30 essential vitamins, minerals, antioxidants, and amino acids at the cellular level, identifying subclinical deficiencies and imbalances that standard blood panels routinely miss. The audit uses intracellular lymphocyte micronutrient testing — analysing nutrient sufficiency within white blood cells to reflect functional cellular reserves rather than transient serum concentrations — combined with serum markers for rapid-turnover nutrients. Performed at an ISO 15189-accredited clinical laboratory and interpreted by a registered dietitian or physician, this panel provides the diagnostic foundation for targeted nutraceutical and dietary intervention in Singapore healthcare and corporate wellness settings.\u003c\/div\u003e\n\u003ch2\u003eClinical Micronutrient Audit — Overview\u003c\/h2\u003e\n\u003cp\u003eMicronutrient deficiency is highly prevalent yet frequently underdiagnosed in Singapore's adult population. Epidemiological studies including the Singapore National Nutrition Survey document suboptimal intakes of Vitamin D (estimated 72–80% insufficiency in multi-ethnic adults), Vitamin B12 (particularly in the elderly and vegetarian population), magnesium, zinc, and folate. Standard health screenings typically assess only 3–5 nutrients, leaving the majority of clinically relevant micronutrient status unmeasured.\u003c\/p\u003e\n\u003cp\u003eThe EMIS+ Clinical Micronutrient Audit addresses this gap through a comprehensive panel of \u0026gt;30 micronutrients using both intracellular lymphocyte testing (SpectraCell-methodology equivalent) and serum assays. Intracellular testing measures nutrient activity within circulating lymphocytes — the gold standard for assessing functional micronutrient sufficiency — as it reflects tissue-level reserves over a 4–6 month period, unlike serum levels which fluctuate with recent dietary intake, inflammation, or hydration status. Results are presented in a clinically structured report with targeted supplementation and dietary recommendations.\u003c\/p\u003e\n\u003ch2\u003ePanel Specifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background: #0057a8; color: #fff;\"\u003e\n\u003cth style=\"padding: 8px; text-align: left; border: 1px solid #ddd;\"\u003eParameter\u003c\/th\u003e\n\u003cth style=\"padding: 8px; text-align: left; border: 1px solid #ddd;\"\u003eSpecification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eTest Methodology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eIntracellular lymphocyte micronutrient analysis + serum \/ plasma assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eNumber of Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u0026gt;30 micronutrients (vitamins, minerals, antioxidants, amino acids)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eVitamins Assessed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eA, B1 (Thiamine), B2 (Riboflavin), B3 (Niacin), B5 (Pantothenate), B6, B7 (Biotin), B9 (Folate), B12, C, D (25-OH), E, K1, K2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eMinerals Assessed\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eCalcium, Magnesium, Zinc, Selenium, Chromium, Copper, Manganese, Iron (with ferritin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eAntioxidants \/ Specialised\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eCoenzyme Q10, Alpha-lipoic acid, Glutathione, Cysteine, Carnitine, Inositol, Choline, Oleic acid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eSample Required\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eBlood draw (venipuncture) at a licensed phlebotomy centre or clinic; Singapore collection points available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eFasting Requirement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e8–12 hours fasting recommended for optimal serum marker accuracy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eISO 15189 accredited clinical laboratory; CLIA-certified analytical facility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eReport Turnaround\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e7–14 business days from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eReport Interpretation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eClinician-reviewed report with personalised supplementation and dietary recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #fff;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eClinical laboratory test performed under MOH Healthcare Services Act licensing; not a standalone HSA-registered medical device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f9f9f9;\"\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003e\u003cstrong\u003ePrice\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding: 8px; border: 1px solid #ddd;\"\u003eSGD 499 (includes panel, lab processing, and clinical interpretation report)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic fatigue and low energy:\u003c\/strong\u003e Identification of deficiencies in B-complex vitamins, Coenzyme Q10, magnesium, and iron that commonly underlie unexplained fatigue in working-age adults, including burnout presentations evaluated by occupational health physicians.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardiovascular risk management:\u003c\/strong\u003e Assessment of Vitamin K2 (vascular calcification prevention), CoQ10 (mitochondrial cardiac function), magnesium (arrhythmia risk), homocysteine pathway co-factors (B6, B9, B12) in patients under cardiologist follow-up.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCognitive decline and neuroprotection:\u003c\/strong\u003e Evaluation of B12, folate, Vitamin D, omega-3\/EPA (via lipid subfractions), and antioxidant status in patients presenting with memory complaints, cognitive fatigue, or early neurodegeneration markers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmune system support:\u003c\/strong\u003e Profiling Vitamin D, Vitamin C, Zinc, Selenium, and Vitamin A in patients with recurrent infections, autoimmune conditions, or post-infectious immune reconstitution needs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePre-conception and fertility:\u003c\/strong\u003e Comprehensive assessment of folate, B12, Vitamin D, iron, zinc, and antioxidant status for women and men planning conception, aligned with MOH pre-conception care guidelines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCorporate executive and preventive health programmes:\u003c\/strong\u003e Annual or biennial micronutrient baseline for high-functioning executives as part of a comprehensive health optimisation programme alongside metabolic, cardiovascular, and hormonal panels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Why is intracellular testing more clinically meaningful than a standard serum micronutrient panel?\u003c\/strong\u003e\u003cbr\u003eA: Serum micronutrient levels reflect transient extracellular concentrations influenced by recent dietary intake, hydration, inflammation (acute-phase reactants suppress serum zinc and selenium during illness), and haemodilution. Intracellular lymphocyte analysis measures the functional nutrient activity within white blood cells — a compartment that reflects cumulative cellular availability over 4–6 months, providing a more accurate assessment of whether nutrients are reaching and being utilised by tissues. A patient may have normal serum Vitamin B6 while simultaneously demonstrating intracellular B6 deficiency affecting neurological function.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Is this test eligible for Medisave or MediShield Life claims in Singapore?\u003c\/strong\u003e\u003cbr\u003eA: Preventive health screening panels, including micronutrient audits, are generally not claimable under Medisave or MediShield Life unless ordered in the context of an MOH-approved chronic disease management programme. Corporate clients may include this test under employee wellness budgets as a taxable or non-taxable benefit depending on MOH\/IRAS guidelines applicable to their scheme. Patients under the CHAS or Pioneer Generation schemes attending polyclinics should enquire about applicable subsidies for physician-ordered investigations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How should results be interpreted and acted upon?\u003c\/strong\u003e\u003cbr\u003eA: The audit report is reviewed by a registered dietitian or physician, who provides a structured interpretation with prioritised intervention recommendations. Supplementation protocols should be tailored to the severity and clinical relevance of each deficiency — not all below-reference values require supplementation, and some deficiencies (e.g., severe Vitamin B12 deficiency) may warrant investigation of aetiology (malabsorption, pernicious anaemia, vegan diet) before supplementation alone is prescribed. Retesting after 3–6 months of targeted intervention is recommended to document response.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can the audit be ordered for corporate health screening without a clinician consultation?\u003c\/strong\u003e\u003cbr\u003eA: EMIS+ offers both direct-to-consumer ordering with a post-result clinician consultation and corporate-programme fulfilment with an integrated medical officer review. For institutional or corporate procurement in Singapore, contact EMIS+ to discuss volume pricing, on-site phlebotomy coordination, and anonymous aggregated reporting for corporate health insights. A licensed physician or registered dietitian sign-off is provided for each individual report regardless of the ordering route.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Clinical Micronutrient Audit used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Clinical Micronutrient Audit by EMIS + is an ostomy care product designed to support stoma management and protect peristomal skin. It is suitable for use with colostomy, ileostomy, and urostomy pouching systems. For personalised advice on your pouching system, consult a Wound, Ostomy and Continence (WOC) nurse at SGH, NUH, CGH, or TTSH in Singapore.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Clinical Micronutrient Audit suitable for all stoma types — colostomy, ileostomy, and urostomy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Most EMIS + stoma care products are designed to be compatible with all stoma types. However, the right product depends on your individual stoma location, output type, and skin condition. An enterostomal therapist (ET nurse) at a Singapore hospital can help you select the most appropriate products for your specific pouching system.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use Clinical Micronutrient Audit correctly?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Always refer to the product instructions included with Clinical Micronutrient Audit. In general, ensure peristomal skin is clean and dry before application, measure your stoma accurately, and change your pouching system every 1–3 days or when leakage is suspected. If you experience peristomal skin irritation, soreness, or persistent leakage, contact a WOC nurse or EMIS+ team for advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Clinical Micronutrient Audit in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Clinical Micronutrient Audit is available from EMIS+ at emis.asia — Singapore's trusted nurse-led stoma supply store. We stock a comprehensive range of ostomy products with fast island-wide delivery. Bulk orders for home care and nursing facilities are welcome. Contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526042779726,"sku":null,"price":499.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"cellular-lipid-matrix","title":"Cellular Lipid Matrix","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Cellular Lipid Matrix is a comprehensive advanced lipid panel and cardiovascular risk assessment offered by EMIS+ in Singapore. It measures LDL particle number and size, oxidised LDL, lipoprotein(a), apolipoprotein B, inflammatory lipid ratios, and cellular membrane lipid composition to stratify cardiovascular disease risk beyond standard cholesterol testing. This diagnostic service is indicated for individuals with familial hypercholesterolaemia risk factors, metabolic syndrome, or those requiring precision cardiovascular risk profiling under clinical guidance.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe EMIS+ Cellular Lipid Matrix is a laboratory-based diagnostic assessment that provides a granular evaluation of lipid metabolism and cardiovascular risk markers. Unlike conventional lipid panels that report only total cholesterol, LDL-C, HDL-C, and triglycerides, this advanced panel quantifies LDL particle number (LDL-P), LDL peak particle size, small dense LDL concentration, oxidised LDL (ox-LDL), lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), and key inflammatory lipid ratios. These markers are recognised by the National Lipid Association (NLA) and the European Atherosclerosis Society (EAS) as superior predictors of residual cardiovascular risk.\u003c\/p\u003e\n\u003cp\u003eAvailable exclusively through EMIS+ at emis.asia in Singapore, the Cellular Lipid Matrix is designed for healthcare professionals, preventive medicine practitioners, and individuals who require precision cardiovascular diagnostics. The test is processed through accredited laboratory facilities that conform to ISO 15189 medical laboratory standards, ensuring analytical accuracy and clinical reliability for each biomarker measured.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eProvider\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eEMIS+ (Essential Medical International Supplies Pte Ltd), Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eTest Type\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eAdvanced Lipid Panel \u0026amp; Cardiovascular Risk Assessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eKey Biomarkers\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eLDL-P (particle number), LDL peak size, sdLDL, ox-LDL, Lp(a), ApoB, Total Cholesterol, HDL-C, LDL-C, Triglycerides, inflammatory lipid ratios\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eSample Requirement\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eFasting venous blood draw (10–12 hour fast recommended)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eTurnaround Time\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003e5–7 working days from sample receipt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eLaboratory Standards\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eISO 15189 accredited medical laboratory; ISO 17025 calibration compliance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eRegulatory Framework\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eSingapore HSA-regulated diagnostic service; laboratory quality management per ISO 15189:2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003eReport Format\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eComprehensive PDF report with reference ranges, risk stratification, and clinical interpretation notes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px; font-weight: bold;\"\u003ePrice\u003c\/td\u003e\n\u003ctd style=\"border: 1px solid #ddd; padding: 8px;\"\u003eSGD 226.00\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eResidual cardiovascular risk assessment in patients with normal LDL-C but elevated ApoB or LDL-P, as recommended by the National Lipid Association (NLA) guidelines\u003c\/li\u003e\n\u003cli\u003eFamilial hypercholesterolaemia screening and risk stratification where standard lipid panels are insufficient for clinical decision-making\u003c\/li\u003e\n\u003cli\u003eMetabolic syndrome evaluation including assessment of atherogenic dyslipidaemia characterised by elevated triglycerides, low HDL-C, and predominance of small dense LDL particles\u003c\/li\u003e\n\u003cli\u003eMonitoring therapeutic efficacy of statin therapy, PCSK9 inhibitors, or lifestyle interventions by tracking LDL particle number reduction alongside LDL-C levels\u003c\/li\u003e\n\u003cli\u003ePreventive cardiovascular health screening for individuals with a family history of premature coronary artery disease or elevated Lp(a) levels, per European Atherosclerosis Society (EAS) consensus recommendations\u003c\/li\u003e\n\u003cli\u003eCellular membrane health assessment for patients presenting with chronic fatigue or inflammatory conditions where lipid peroxidation markers may inform clinical management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow does the Cellular Lipid Matrix differ from a standard lipid panel available at Singapore polyclinics?\u003c\/h3\u003e\n\u003cp\u003eA standard lipid panel measures four markers: total cholesterol, LDL-C, HDL-C, and triglycerides. The Cellular Lipid Matrix extends this to include LDL particle number and size distribution, oxidised LDL, lipoprotein(a), and apolipoprotein B. Research published in the Journal of Clinical Lipidology demonstrates that LDL-P and ApoB are superior predictors of atherosclerotic cardiovascular disease events compared with LDL-C alone, particularly in patients with discordant LDL-C and LDL-P values.\u003c\/p\u003e\n\u003ch3\u003eIs fasting required before the blood draw for this test?\u003c\/h3\u003e\n\u003cp\u003eYes. A 10–12 hour overnight fast is recommended to ensure accurate measurement of triglycerides and lipoprotein subfractions. Water consumption is permitted during the fasting period. Clinicians should advise patients to maintain their usual medication schedule unless specifically instructed otherwise.\u003c\/p\u003e\n\u003ch3\u003eWho should consider ordering the Cellular Lipid Matrix?\u003c\/h3\u003e\n\u003cp\u003eThis test is clinically indicated for individuals with a family history of premature cardiovascular disease, patients with metabolic syndrome or insulin resistance, those on lipid-lowering therapy requiring detailed treatment monitoring, and anyone whose standard lipid panel results appear normal but who has other cardiovascular risk factors. The European Atherosclerosis Society recommends Lp(a) measurement at least once in every adult's lifetime for cardiovascular risk assessment.\u003c\/p\u003e\n\u003ch3\u003eAre the results reviewed by a medical professional?\u003c\/h3\u003e\n\u003cp\u003eThe laboratory report includes reference ranges and interpretive notes. EMIS+ recommends that all results be reviewed with a qualified healthcare provider — such as a cardiologist, endocrinologist, or preventive medicine physician — who can contextualise the findings within the patient's complete clinical history and guide appropriate therapeutic interventions.\u003c\/p\u003e\n\u003ch3\u003eCan this test be used for monitoring statin or PCSK9 inhibitor therapy?\u003c\/h3\u003e\n\u003cp\u003eYes. Tracking LDL-P and ApoB levels provides a more precise measure of therapeutic response than LDL-C alone. The NLA recommends ApoB or LDL-P as secondary treatment targets, particularly in patients who achieve LDL-C goals but retain elevated particle counts, a condition known as LDL-C\/LDL-P discordance that is associated with residual cardiovascular risk.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Cellular Lipid Matrix used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Lipid Matrix by EMIS + is a medical supply item used in clinical and home care settings. It is designed for use by healthcare professionals and trained home care users. Always follow the manufacturer's instructions and relevant clinical guidelines when using medical devices. For guidance on proper use, consult your healthcare provider.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Cellular Lipid Matrix suitable for home use?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Some EMIS + products are designed for both clinical and home use, while others are intended for use by trained healthcare professionals only. Check the product labelling and consult your doctor, nurse, or pharmacist to confirm whether Cellular Lipid Matrix is appropriate for home use in your situation. EMIS+ nurses are available to advise — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Does Cellular Lipid Matrix require a prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"In Singapore, many medical supplies and devices do not require a prescription for purchase. However, certain controlled medical devices may require professional authorisation. EMIS+ sells products in compliance with HSA (Health Sciences Authority) Singapore regulations. Contact us at emis.asia if you need clarification on a specific product.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Cellular Lipid Matrix in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Lipid Matrix is available from EMIS+ at emis.asia, Singapore's trusted nurse-led medical supply store. We serve hospitals, nursing homes, clinics, and home care users across the island with fast delivery and competitive pricing. Bulk and institutional orders are welcome.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526043435086,"sku":null,"price":226.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"intracellular-nad-assessment","title":"Intracellular NAD+ Assessment","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eIntracellular NAD+ Assessment — Cellular Energy Currency and Longevity Cofactor Quantification (SGD 600)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nThe Intracellular NAD+ Assessment is EMIS+'s dedicated quantification of nicotinamide adenine dinucleotide (NAD+) — the central metabolic cofactor and electron carrier whose intracellular concentration declines approximately 50% between ages 20 and 70, mechanistically impairing the activity of sirtuins (SIRT1–7), poly-ADP-ribose polymerases (PARP1\/2), and CD38 NADase — three enzyme families governing DNA repair fidelity, mitochondrial biogenesis, circadian rhythm entrainment, and inflammatory resolution. Measured by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) from peripheral blood mononuclear cells (PBMCs), the assessment provides absolute intracellular NAD+ concentration (pmol\/mg protein), the NAD+\/NADH redox ratio, and NAMPT (nicotinamide phosphoribosyltransferase) enzyme activity — the rate-limiting step of NAD+ biosynthesis via the salvage pathway. Results are benchmarked against an age\/sex-stratified normative reference database to yield an NAD+ Depletion Index and biological age-equivalent NAD+ status.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eNAD+ Biology and Age-Related Decline:\u003c\/strong\u003e NAD+ functions simultaneously as a redox carrier in oxidative phosphorylation (NADH → NAD+ in the electron transport chain, Complex I) and as a substrate for non-redox signalling enzymes. The sirtuins (SIRT1–7) — class III histone deacylases requiring NAD+ stoichiometrically — are activated when NAD+ is abundant and silenced when NAD+ falls below a critical threshold (~100 µM intracellular). SIRT1 and SIRT3 regulate mitochondrial biogenesis via PGC-1α deacetylation; SIRT6 maintains telomere stability and DNA double-strand break repair; SIRT1 modulates the BMAL1\/CLOCK circadian transcription complex. PARP1, the primary DNA damage sensor, consumes NAD+ per ADP-ribosylation event — in the context of excessive DNA damage (from oxidative stress, UV, ionising radiation), PARP hyperactivation can deplete cellular NAD+ within minutes, creating a bioenergetic crisis. CD38 — a multifunctional ectoenzyme expressed on immune cells — is the dominant NAD+ consumer in aged tissue, with CD38 expression increasing 2–3× between ages 25–70 (Camacho-Pereira et al., Cell Metabolism 2016), explaining the paradox of reduced NAD+ despite adequate dietary precursor intake.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eMeasurement Methodology — LC-MS\/MS:\u003c\/strong\u003e PBMC isolation from fresh venous blood (within 2 hours, standardised collection protocol) is performed by Ficoll density-gradient centrifugation. Cell pellets are lysed in perchloric acid to terminate metabolic activity, and the lysate is processed by reverse-phase LC-MS\/MS using isotope-labelled internal standards (¹³C₅-NAD+) for absolute quantification. This method achieves an analytical sensitivity of 0.5 pmol\/mg protein with inter-assay CV \u0026lt;8%. The NAD+\/NADH ratio is calculated from simultaneous LC-MS\/MS quantification of reduced NADH. NAMPT activity is measured by a fluorometric enzymatic cycling assay detecting nicotinamide mononucleotide (NMN) production rate (nmol NMN\/hr\/mg protein). The PBMC-based measurement reflects the intracellular NAD+ status of circulating immune cells — the most accessible surrogate for systemic NAD+ homeostasis, validated against tissue biopsies in the Rajman et al. framework (Cell Metabolism 2018).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eNAD+ Depletion Index and Clinical Risk Stratification:\u003c\/strong\u003e The NAD+ Depletion Index integrates absolute NAD+ concentration percentile rank, NAD+\/NADH ratio deviation from age-matched norm, and NAMPT activity z-score into a composite deprivation metric. An Index ≥+1.5 SD below age-matched mean identifies individuals whose sirtuin and PARP activity is likely substrate-limited — where NAD+ precursor supplementation (NMN or NR at doses of 300–1000 mg\/day) is supported by Phase I\/II human trial evidence. Irie et al. (npj Aging and Mechanisms of Disease 2020) demonstrated that oral NMN 250 mg\/day for 12 weeks significantly increased whole blood NAD+ in healthy older adults (mean age 65, p\u0026lt;0.001 vs. placebo). Dolopikou et al. (European Journal of Nutrition 2020) showed NR 1000 mg\/day increased PBMC NAD+ by 2.7× over 21 days. The assessment enables pre\/post supplementation monitoring to confirm individual pharmacological response — essential given the 3–5× inter-individual variability in NAD+ biosynthetic capacity documented in the Yoshino et al. CELL 2021 study.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCombination with EMIS+ Longevity Panel:\u003c\/strong\u003e The Intracellular NAD+ Assessment integrates with EMIS+ TrueAge epigenetic clocks, Cellular Senescence Dual-Panel, and EMIS+ Longevity Core for a complete mechanistic longevity map: epigenetic clock → rate of biological age accumulation; Cellular Senescence Dual-Panel → senescent cell burden driving SASP; NAD+ Assessment → sirtuin and PARP substrate availability driving DNA repair and circadian fidelity. Low NAD+ in the context of high p16INK4a\/SASP identifies a senescence-associated NAD+ depletion phenotype (Chini et al., Cell Reports 2020) where combined senolytic + NAD+ precursor therapy is mechanistically additive.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eIntracellular NAD+ Assessment — Measurement Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:25%;\"\u003eParameter\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:25%;\"\u003eMethod\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:25%;\"\u003eUnits \/ Sensitivity\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:25%;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIntracellular NAD+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLC-MS\/MS; ¹³C₅-NAD+ isotope internal standard; PBMC lysate\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003epmol\/mg protein; LoD 0.5 pmol\/mg; CV \u0026lt;8%\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePrimary sirtuin\/PARP substrate; declines ~50% ages 20–70\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIntracellular NADH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLC-MS\/MS; simultaneous with NAD+ measurement\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003epmol\/mg protein\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eElectron transport chain substrate; mitochondrial redox state indicator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eNAD+\/NADH Ratio\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDerived from LC-MS\/MS NAD+\/NADH measurements\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDimensionless ratio; age-matched percentile\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCellular redox balance; mitochondrial OXPHOS efficiency; metabolic health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eNAMPT Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eFluorometric enzymatic cycling assay; NMN production rate\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003enmol NMN\/hr\/mg protein\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRate-limiting salvage pathway enzyme; predicts NAD+ biosynthetic capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eNAD+ Depletion Index\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite z-score: NAD+ percentile + NAD+\/NADH deviation + NAMPT z-score\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSD from age\/sex-matched norm\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIdentifies substrate-limited sirtuin\/PARP activity; NMN\/NR supplementation threshold\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePBMC Isolation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eFicoll density-gradient centrifugation; processed within 2 hours of collection\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eStandardised collection protocol; cold-chain maintained\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCirculating immune cell surrogate for systemic NAD+ homeostasis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSupplementation Monitoring\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRepeat assessment at 6–12 weeks post-NMN\/NR initiation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e% change from baseline NAD+\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eConfirms individual pharmacological response; dose titration guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eEvidence Base\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIrie et al. npj Aging 2020; Yoshino et al. Cell 2021; Rajman et al. Cell Metab 2018\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNMN\/NR Phase I\/II human trial data\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSupports 300–1000 mg\/day NMN\/NR dosing at confirmed depletion threshold\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eISO 15189:2022; CAP accreditation; Singapore HSA laboratory licensing\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eIFCC-traceable; external QA programmes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eISO 15189:2022; IFCC; Singapore HSA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Intracellular NAD+ Assessment\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is intracellular PBMC NAD+ measurement superior to whole-blood or plasma NAD+ for clinical decision-making?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eWhole-blood NAD+ is dominated by erythrocyte NAD+ — which reflects red blood cell redox metabolism rather than the nuclear\/mitochondrial NAD+ pool governing sirtuin and PARP activity. Erythrocytes lack nuclei and mitochondria, making their NAD+ content irrelevant to the transcriptional and DNA repair functions that decline with age. Plasma NAD+ is present at picomolar concentrations — far below the intracellular millimolar range where enzyme kinetics operate — and reflects extracellular NAD+ flux rather than cellular substrate availability. PBMC-based intracellular measurement — after PBMC isolation and protein-precipitation cell lysis — directly quantifies the NAD+ concentration available to nuclear SIRT1\/SIRT6, mitochondrial SIRT3, and PARP1 within the cells most reflective of systemic immune and metabolic ageing. The Rajman, Chwalek and Sinclair Cell Metabolism 2018 review establishes PBMC NAD+ as the clinically validated surrogate measure for NAD+ precursor trial monitoring, as used in the Irie 2020 NMN trial and Yoshino 2021 CELL study. EMIS+ uses the PBMC LC-MS\/MS methodology aligned with these published human trial protocols for direct result comparability.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: What is NAMPT, and why does its activity measurement add clinical value beyond NAD+ concentration alone?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eNicotinamide phosphoribosyltransferase (NAMPT) catalyses the rate-limiting first step of the NAD+ salvage pathway — the conversion of nicotinamide (NAM) to nicotinamide mononucleotide (NMN), which is then converted to NAD+ by NMNAT enzymes. NAMPT activity determines an individual's endogenous NAD+ biosynthetic ceiling independent of dietary precursor availability. Two distinct NAD+ depletion phenotypes exist: (1) NAMPT-limited: reduced NAMPT activity constrains NAD+ production even when precursor availability is adequate — NMN supplementation (bypassing the NAMPT step by providing NMN directly) is preferred over NR (which requires NAMPT to convert NAM back to NMN via the salvage pathway); (2) Substrate-limited: adequate NAMPT activity but inadequate dietary NAM\/NR\/NMN precursor intake — either NR or NMN supplementation is effective. Without NAMPT measurement, NR supplementation may be ineffective in NAMPT-limited individuals, explaining the significant inter-individual variation in NAD+ response reported by Yoshino et al. (Cell 2021). The NAMPT activity assay in the EMIS+ Intracellular NAD+ Assessment enables precision-guided precursor selection — a clinically meaningful distinction given the cost differential between NMN (approximately USD 1–3 per 500mg dose) and NR (approximately USD 0.5–1.5 per 250mg dose) at therapeutic doses.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the current Phase I\/II human clinical evidence for NMN and NR supplementation raising intracellular NAD+?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eMultiple randomised, placebo-controlled human trials confirm oral NMN and NR supplementation raises intracellular NAD+ in peripheral blood cells. Key evidence: (1) Irie et al. npj Aging and Mechanisms of Disease (2020): NMN 250 mg\/day for 12 weeks in healthy older adults (mean age 65) increased whole blood NAD+ significantly vs. placebo (p\u0026lt;0.001); muscle insulin sensitivity and physical performance (grip strength, walking speed) improved in the highest-baseline-NAD+-response subgroup. (2) Yoshino et al. Cell (2021): NMN 250 mg\/day for 10 weeks in postmenopausal women with prediabetes increased muscle NAD+ content and improved insulin-stimulated glucose disposal, demonstrating tissue-level functional NAD+ restoration. (3) Dolopikou et al. European Journal of Nutrition (2020): NR 1000 mg\/day in older adults (mean age 73) for 21 days increased PBMC NAD+ 2.7× vs. baseline, with significant reduction in inflammatory markers including IL-6. (4) Martens et al. Nature Communications (2022): NR 1000 mg\/day for 6 weeks in healthy middle-aged\/older adults significantly raised blood NAD+ metabolome, reduced arterial stiffness and blood pressure. (5) Elhassan et al. Cell Reports (2019): NR 1000 mg\/day elevated NAD+ metabolism in skeletal muscle, liver, and adipose tissue with concurrent SIRT1\/SIRT3 activation markers. The EMIS+ assessment provides the pre-supplementation NAD+ baseline necessary to confirm a below-threshold status before initiating supplementation, and the post-supplementation follow-up assessment to confirm individual response.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: How do sirtuins depend on NAD+, and which sirtuin functions are most impacted by age-related NAD+ decline?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eSirtuins (SIRT1–7) are class III NAD+-dependent protein deacylases that consume one molecule of NAD+ per deacylation reaction, producing nicotinamide (NAM) and O-acetyl-ADP-ribose as by-products. Because sirtuins are kinetically dependent on NAD+ concentration rather than simply requiring its presence as a cofactor, their activity falls proportionally as intracellular NAD+ declines with age. SIRT1 (nuclear\/cytoplasmic): deacetylates PGC-1α (activating mitochondrial biogenesis and oxidative phosphorylation), p53 (suppressing senescence and apoptosis), and the BMAL1\/CLOCK complex (maintaining circadian rhythm amplitude). SIRT1 loss drives circadian disruption, accelerated epigenetic ageing, and impaired stress resistance. SIRT3 (mitochondrial matrix): deacetylates and activates Complex I (NADH dehydrogenase), Complex II, and antioxidant enzymes (SOD2\/MnSOD), reducing mitochondrial ROS production. SIRT3 knockout mice show accelerated metabolic syndrome, hearing loss, and cardiac fibrosis. SIRT6 (nuclear chromatin): maintains telomere structure by deacetylating H3K9 and H3K56 at telomere regions, and promotes double-strand break repair by recruiting DNA-PKcs. SIRT6 deficiency in mice produces premature ageing phenotypes including lordokyphosis, metabolic syndrome, and shortened lifespan. SIRT7 (nucleolar): regulates ribosomal RNA transcription and proteostasis. Age-related NAD+ decline simultaneously impairs all seven sirtuins, explaining why NAD+ depletion phenotypes manifest as multisystem biological age acceleration rather than a single-organ phenotype.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: How should the Intracellular NAD+ Assessment results be interpreted alongside exercise and dietary interventions before initiating NMN\/NR supplementation?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eBefore initiating NMN or NR supplementation, the Intracellular NAD+ Assessment report evaluates whether lifestyle-accessible NAD+ optimisation has been maximised. Endurance exercise robustly upregulates NAMPT expression in skeletal muscle (Costford et al., J Physiol 2010; Canto et al., Cell 2010) — individuals who are sedentary (fewer than 75 minutes vigorous or 150 minutes moderate aerobic activity per week per ACC\/AHA guidelines) may achieve clinically significant NAD+ restoration through exercise alone without supplementation. Caloric restriction and time-restricted eating (16:8 TRE) activate AMPK, suppressing mTORC1 and CD38 expression — reducing NAD+ consumption and allowing recovery. Niacin (vitamin B3, NAM) dietary adequacy is the primary precursor assessment: individuals with dietary intake below the RDA of 16 mg NE\/day (adult male) or 14 mg NE\/day (adult female) will show NAMPT-substrate depletion correctable with dietary optimisation before considering supplemental NMN\/NR. The NAD+ Depletion Index threshold for supplementation recommendation is calibrated at ≥1.5 SD below age-matched mean — a level at which lifestyle optimisation alone has been insufficient in the CALERIE-2 and HERITAGE family study data to restore NAD+ to age-appropriate levels, and where Phase II trial evidence (Irie 2020; Yoshino 2021) demonstrates supplemental NMN\/NR provides additional, measurable restoration. The post-supplementation follow-up assessment at 6–12 weeks objectively confirms individual response, enabling dose titration or alternative precursor switching (NMN vs. NR) based on measured intracellular NAD+ change.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Intracellular NAD+ Assessment — PBMC NAD+\/NADH + NAMPT Activity Measurement\",\n  \"description\": \"EMIS+ Intracellular NAD+ Assessment: LC-MS\/MS PBMC NAD+ and NADH quantification (pmol\/mg protein), NAD+\/NADH redox ratio, NAMPT enzymatic activity. NAD+ Depletion Index. NMN vs NR precursor selection. Supplementation monitoring. ISO 15189:2022. SGD 600. Singapore.\",\n  \"sku\": \"EMIS-NAD-600\",\n  \"brand\": {\"@type\": \"Brand\", \"name\": \"EMIS+\"},\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"600.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/intracellular-nad-assessment\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Primary Measurement\", \"value\": \"Intracellular NAD+ by LC-MS\/MS; ¹³C₅-NAD+ isotope internal standard; PBMC lysate\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Additional Parameters\", \"value\": \"Intracellular NADH; NAD+\/NADH ratio; NAMPT enzymatic activity (nmol NMN\/hr\/mg protein)\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Composite Output\", \"value\": \"NAD+ Depletion Index (SD from age\/sex-matched norm)\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Clinical Utility\", \"value\": \"Sirtuin\/PARP substrate status; NMN vs NR precursor selection; supplementation monitoring\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Evidence Base\", \"value\": \"Irie npj Aging 2020; Yoshino Cell 2021; Martens Nat Commun 2022; Rajman Cell Metab 2018\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited; IFCC-traceable; Singapore HSA laboratory licensing\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e The Intracellular NAD+ Assessment is performed within an ISO 15189:2022-accredited laboratory with CAP external quality assurance and Singapore HSA laboratory licensing. LC-MS\/MS NAD+ quantification uses isotope dilution methodology (¹³C₅-NAD+ internal standard) traceable to NIST Standard Reference Material 8327 (nucleotide quantification) with inter-assay CV \u0026lt;8% and intra-assay CV \u0026lt;5%. PBMC isolation follows standardised Ficoll-Paque Plus (1.077 g\/mL) density gradient centrifugation with cold-chain preservation (2–8°C) from blood draw to cell lysis within 2 hours, consistent with the PBMC processing protocol validated in Irie et al. 2020 and Yoshino et al. 2021. NAMPT enzymatic activity assay uses a fluorometric cycling method with NMN fluorescence detection, calibrated against purified recombinant human NAMPT (specific activity reference). The NAD+ Depletion Index normative database is constructed from age\/sex-stratified PBMC NAD+ values from healthy non-smoking, non-diabetic adults aged 25–75, referenced to the age-related decline trajectory described in Camacho-Pereira et al. Cell Metabolism 2016 and Massudi et al. PLoS ONE 2012. Supplementation guidance references the NIA-funded NMN and NR human clinical trial evidence base through 2024 publication cutoff. NMN and NR are classified as health supplements in Singapore and are not registered as therapeutic products under the Singapore Health Sciences Authority Therapeutic Products Act. Advice regarding NMN\/NR supplementation is provided as nutritional health information; therapeutic intervention decisions remain the purview of licensed Singapore MOH-registered physicians.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Intracellular NAD+ Assessment for digestive health?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Intracellular NAD+ Assessment by EMIS + supports digestive health and gut wellbeing. For individuals with digestive concerns such as IBS, bloating, or irregular bowel habits, targeted gut health supplementation may complement a balanced diet and lifestyle. Always consult a doctor or dietitian before starting supplements for digestive conditions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Intracellular NAD+ Assessment?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Intracellular NAD+ Assessment may benefit adults seeking to support digestive health, those recovering from antibiotic use, individuals with irregular bowel habits, or those with conditions affecting gut microbiome balance. It is not a substitute for medical treatment. Consult your GP or gastroenterologist — available at SGH, NUH, Mount Elizabeth, and Raffles Hospital in Singapore — for personalised advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How should I take Intracellular NAD+ Assessment for best results?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Intracellular NAD+ Assessment packaging or as directed by your healthcare provider. Consistency is key — most gut health supplements take 4–8 weeks of regular use to show measurable benefits. Store as directed on the label. Do not exceed the recommended daily dose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Intracellular NAD+ Assessment in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Intracellular NAD+ Assessment is available at EMIS+ (emis.asia) with fast Singapore island-wide delivery. We carry a curated range of clinically-informed digestive health supplements. Visit emis.asia or contact our team for product recommendations.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526044319822,"sku":null,"price":600.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"metabolic-engine-tracker","title":"Metabolic Engine Tracker","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Metabolic Engine Tracker is a comprehensive metabolic health assessment offered by EMIS+ in Singapore that measures resting metabolic rate (RMR), substrate oxidation, glucose regulation, and hormonal biomarkers to produce an integrated metabolic health profile. It utilises indirect calorimetry and validated blood biomarker panels to quantify energy expenditure, insulin sensitivity, and mitochondrial efficiency. This assessment is indicated for metabolic syndrome screening, weight management planning, athletic performance optimisation, and longitudinal metabolic health monitoring in adults.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe EMIS+ Metabolic Engine Tracker employs indirect calorimetry, the clinical reference standard for measuring resting metabolic rate (RMR), combined with a targeted blood biomarker panel to provide a comprehensive metabolic health assessment. Indirect calorimetry measures oxygen consumption (VO2) and carbon dioxide production (VCO2) through breath analysis, calculating respiratory exchange ratio (RER) to determine the proportion of energy derived from carbohydrate versus fat oxidation. This methodology is endorsed by the American College of Sports Medicine (ACSM) and validated against the Weir equation (ISO 80601-2-55) for metabolic rate determination.\u003c\/p\u003e\n\u003cp\u003eThe accompanying blood panel assesses fasting glucose, fasting insulin, HbA1c, lipid profile (total cholesterol, LDL, HDL, triglycerides), thyroid function (TSH, free T3, free T4), cortisol, and inflammatory markers (hs-CRP). These biomarkers are analysed by CAP-accredited and ISO 15189-certified laboratories in Singapore. Results are interpreted by qualified healthcare professionals and integrated into a personalised metabolic optimisation plan addressing nutrition, exercise prescription, sleep, and stress management aligned with Singapore Ministry of Health preventive health guidelines.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProvider\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEMIS+ Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAssessment Components\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndirect calorimetry (RMR) + blood biomarker panel + body composition metrics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMetabolic Measurements\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResting metabolic rate (kcal\/day), respiratory exchange ratio (RER), substrate oxidation rates (g\/min fat and carbohydrate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBlood Biomarkers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFasting glucose, fasting insulin, HbA1c, HOMA-IR, lipid panel, TSH, free T3\/T4, cortisol, hs-CRP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMethodology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOpen-circuit indirect calorimetry per Weir equation; venous blood draw analysed by ISO 15189-certified laboratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAssessment Duration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately 60–90 minutes (includes fasting breath test and blood draw)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFasting Requirement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e10–12 hour overnight fast; no caffeine or vigorous exercise 24 hours prior\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReference Standards\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eISO 80601-2-55 (respiratory gas analysers); ISO 15189 (medical laboratories); ACSM metabolic testing guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Framework\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHSA Singapore registered medical devices; laboratory services licensed under MOH Singapore Private Hospitals and Medical Clinics Act\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReport Delivery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDigital report within 3–5 working days with clinical interpretation and personalised recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eQuality Assurance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCAP-accredited laboratory; equipment calibrated per manufacturer ISO 17025 protocols\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMetabolic syndrome screening by quantifying insulin resistance (HOMA-IR), dyslipidaemia, and central adiposity markers in accordance with IDF and ATP III diagnostic criteria\u003c\/li\u003e\n\u003cli\u003eWeight management programme design through precise RMR measurement, enabling evidence-based caloric prescription rather than estimation-based approaches\u003c\/li\u003e\n\u003cli\u003eThyroid function assessment to identify subclinical hypothyroidism or hyperthyroidism contributing to metabolic dysfunction\u003c\/li\u003e\n\u003cli\u003eAthletic performance profiling to determine fuel utilisation efficiency, fat oxidation capacity, and metabolic flexibility during rest and exercise\u003c\/li\u003e\n\u003cli\u003eType 2 diabetes risk stratification using fasting insulin, HbA1c, and glucose-insulin dynamics aligned with ADA and MOH Singapore clinical practice guidelines\u003c\/li\u003e\n\u003cli\u003eLongevity health baseline assessment for adults seeking to optimise mitochondrial function, inflammatory status, and hormonal balance through data-driven interventions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the difference between estimated and measured metabolic rate?\u003c\/h3\u003e\n\u003cp\u003eEstimation equations such as Harris-Benedict and Mifflin-St Jeor predict metabolic rate from age, sex, height, and weight, but these formulae carry prediction errors of 10–30% at the individual level. Indirect calorimetry, as used in the Metabolic Engine Tracker, directly measures oxygen consumption and carbon dioxide production to calculate actual metabolic rate with a precision error below 5%. The American College of Sports Medicine (ACSM) recommends measured RMR for clinical nutrition planning.\u003c\/p\u003e\n\u003ch3\u003eWhat does the respiratory exchange ratio (RER) reveal?\u003c\/h3\u003e\n\u003cp\u003eThe respiratory exchange ratio is the ratio of CO2 produced to O2 consumed during metabolism. An RER of 0.7 indicates predominant fat oxidation, while 1.0 indicates predominant carbohydrate oxidation. Values between 0.7 and 1.0 reflect mixed substrate utilisation. This metric helps identify metabolic inflexibility, a condition associated with insulin resistance and metabolic syndrome, and guides nutrition interventions to improve fat oxidation capacity.\u003c\/p\u003e\n\u003ch3\u003eHow should I prepare for the metabolic assessment?\u003c\/h3\u003e\n\u003cp\u003ePatients must fast for 10–12 hours before the assessment (water is permitted). Avoid caffeine, alcohol, and vigorous exercise for 24 hours prior. Arrive in a rested state and wear comfortable clothing. These standardised conditions, recommended by ACSM metabolic testing protocols, ensure accurate baseline measurements of metabolic rate and substrate utilisation.\u003c\/p\u003e\n\u003ch3\u003eWho benefits most from a metabolic health assessment in Singapore?\u003c\/h3\u003e\n\u003cp\u003eIndividuals with unexplained weight gain or difficulty losing weight, those with family history of metabolic syndrome or type 2 diabetes, athletes seeking to optimise fuel efficiency, and adults pursuing preventive longevity health strategies. Singapore's multiethnic population has varying metabolic risk profiles, and the Ministry of Health identifies metabolic disease as a national health priority, making personalised metabolic assessment particularly relevant.\u003c\/p\u003e\n\u003ch3\u003eHow often should metabolic testing be repeated?\u003c\/h3\u003e\n\u003cp\u003eFor individuals undergoing dietary, exercise, or pharmacological interventions, repeat assessment at 3–6 month intervals provides meaningful data on metabolic adaptation. Stable individuals may benefit from annual reassessment to track age-related metabolic changes. Serial testing enables clinicians to quantify intervention efficacy and adjust recommendations based on objective metabolic data rather than subjective outcomes.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Metabolic Engine Tracker used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Metabolic Engine Tracker by EMIS + is a advanced wound dressing used for wound management. It is designed to support moist wound healing, manage exudate, and protect the wound bed from contamination. It is commonly used in Singapore hospitals and home care settings for chronic wounds, post-surgical wounds, and ulcers. Always follow the guidance of your wound care nurse or doctor when selecting a dressing.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How often should Metabolic Engine Tracker be changed?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Metabolic Engine Tracker should generally be changed every 1–7 days depending on wound type and exudate. However, frequency should always be guided by your wound care nurse or clinician based on wound size, exudate level, and signs of infection. Do not leave any dressing in place if it becomes saturated, dislodged, or if the wound shows signs of infection such as increased redness, warmth, or discharge.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Metabolic Engine Tracker available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes, Metabolic Engine Tracker is available for purchase from EMIS+ (emis.asia) without a prescription for general wound care use. For complex or chronic wounds, we strongly recommend consulting a wound care nurse, GP, or specialist at a Singapore hospital such as SGH, NUH, TTSH, or CGH before selecting a dressing. EMIS+ nurses can also provide product guidance — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Metabolic Engine Tracker in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Metabolic Engine Tracker is available from EMIS+ at emis.asia, Singapore's nurse-led medical supply store. We offer fast island-wide delivery, competitive pricing, and bulk ordering for healthcare facilities and home care users. Visit emis.asia or contact our team for assistance.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526047924302,"sku":null,"price":199.0,"currency_code":"SGD","in_stock":true}]},{"product_id":"executive-brain-span-audit-mci","title":"Executive Brain-Span Audit (MCI)","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e The Executive Brain-Span Audit (MCI) is a clinical-grade cognitive screening service offered by EMIS+ in Singapore, designed to detect early-stage Mild Cognitive Impairment through standardised neuropsychological testing batteries covering executive function, memory recall, and processing speed. The assessment follows internationally recognised MCI diagnostic criteria aligned with the National Institute on Aging and Alzheimer's Association (NIA-AA) research framework. It is indicated for adults aged 40 and above seeking proactive cognitive health monitoring, particularly those with cardiovascular risk factors, family history of neurodegenerative disease, or occupational cognitive demands.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eThe Executive Brain-Span Audit (MCI) at EMIS+ is a comprehensive cognitive health assessment service available exclusively through emis.asia in Singapore. This clinical-grade screening protocol employs validated neuropsychological instruments to evaluate executive function, episodic memory, visuospatial ability, language fluency, and processing speed. The assessment generates a personalised brain longevity profile that quantifies cognitive reserve and identifies domains requiring targeted intervention.\u003c\/p\u003e\n\u003cp\u003eEarly detection of Mild Cognitive Impairment represents a critical window for therapeutic intervention. Peer-reviewed longitudinal studies demonstrate that individuals identified at the MCI stage who receive structured cognitive rehabilitation, lifestyle modification, and pharmacological support where appropriate experience significantly better cognitive trajectories than those diagnosed after progression to dementia. The EMIS+ protocol integrates evidence-based screening methodologies consistent with NIA-AA 2018 research framework criteria and Singapore Ministry of Health (MOH) clinical practice guidelines for dementia management.\u003c\/p\u003e\n\u003ch2\u003eService Specifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold; width: 40%;\"\u003eProvider\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eEMIS+ (Essential Medical International Supplies Pte Ltd), Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eAssessment Type\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eNeuropsychological Screening Battery — Mild Cognitive Impairment (MCI)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eCognitive Domains Assessed\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eExecutive Function, Episodic Memory, Working Memory, Processing Speed, Visuospatial Function, Language Fluency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eValidated Instruments\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eMoCA (Montreal Cognitive Assessment), Trail Making Test (TMT-A\/B), Digit Span, Category Fluency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eDiagnostic Framework\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eNIA-AA 2018 Research Framework; DSM-5 Mild Neurocognitive Disorder Criteria\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eTarget Population\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eAdults aged 40+; individuals with cardiovascular risk factors, family history of neurodegeneration, or high cognitive occupational demands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eDelivery\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eIn-person clinical assessment, Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eOutput\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003ePersonalised Brain Longevity Profile with domain-specific scoring and intervention recommendations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003eRegulatory Alignment\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eSingapore MOH Clinical Practice Guidelines on Dementia; NIA-AA 2018 Framework; ISO 15189 accredited laboratory partners where applicable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom: 1px solid #ddd;\"\u003e\n\u003ctd style=\"padding: 8px; font-weight: bold;\"\u003ePrice\u003c\/td\u003e\n\u003ctd style=\"padding: 8px;\"\u003eSGD 179.00\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eProactive cognitive health screening for adults aged 40 and above as part of annual executive health programmes\u003c\/li\u003e\n\u003cli\u003eEarly detection of Mild Cognitive Impairment in individuals presenting with subjective memory complaints not yet meeting dementia diagnostic thresholds\u003c\/li\u003e\n\u003cli\u003eBaseline cognitive profiling for patients initiating cardiovascular, metabolic, or neurological treatment protocols where cognitive monitoring is recommended\u003c\/li\u003e\n\u003cli\u003ePost-concussion or post-anaesthetic cognitive function assessment to establish recovery benchmarks\u003c\/li\u003e\n\u003cli\u003eLongitudinal cognitive monitoring for individuals with APOE-e4 carrier status or first-degree family history of Alzheimer disease\u003c\/li\u003e\n\u003cli\u003eOccupational cognitive fitness evaluation for professionals in safety-critical roles (aviation, healthcare, finance)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What is the clinical basis for MCI screening at age 40?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA: The NIA-AA 2018 research framework and epidemiological data from the Singapore Longitudinal Ageing Study (SLAS) indicate that subclinical cognitive changes can begin in the fourth decade. Early screening establishes a cognitive baseline that enables detection of meaningful decline over time, consistent with recommendations from the American Academy of Neurology (AAN) practice parameter on MCI.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Which neuropsychological instruments are used in this audit?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA: The assessment employs internationally validated tools including the Montreal Cognitive Assessment (MoCA), Trail Making Test Parts A and B, Digit Span Forward and Backward, and Category Fluency testing. These instruments are recommended by the Singapore MOH Clinical Practice Guidelines on Dementia and align with NIA-AA core clinical criteria for MCI diagnosis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How does this differ from a standard memory screening?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA: Standard memory screenings such as the MMSE assess global cognitive function with limited sensitivity for MCI. The Executive Brain-Span Audit employs a multi-domain neuropsychological battery with specific attention to executive function — the cognitive domain most predictive of functional decline and occupational performance deterioration in early MCI presentations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Is this assessment recognised by Singapore healthcare authorities?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA: The screening instruments and diagnostic criteria used are consistent with Singapore Ministry of Health (MOH) Clinical Practice Guidelines on Dementia and internationally recognised frameworks (NIA-AA, DSM-5). Results can be shared with referring physicians for clinical decision-making and further diagnostic workup including neuroimaging if indicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: Can I use MediFund, MediSave, or insurance to pay for this assessment?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA: Cognitive screening services may qualify for reimbursement under certain private health insurance plans or corporate wellness programmes. MediSave coverage for cognitive screening is subject to MOH regulations and referring physician assessment. Please consult your insurance provider or contact EMIS+ at emis.asia for specific coverage enquiries.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Executive Brain-Span Audit (MCI) used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Executive Brain-Span Audit (MCI) by EMIS + is an ostomy care product designed to support stoma management and protect peristomal skin. It is suitable for use with colostomy, ileostomy, and urostomy pouching systems. For personalised advice on your pouching system, consult a Wound, Ostomy and Continence (WOC) nurse at SGH, NUH, CGH, or TTSH in Singapore.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Executive Brain-Span Audit (MCI) suitable for all stoma types — colostomy, ileostomy, and urostomy?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Most EMIS + stoma care products are designed to be compatible with all stoma types. However, the right product depends on your individual stoma location, output type, and skin condition. An enterostomal therapist (ET nurse) at a Singapore hospital can help you select the most appropriate products for your specific pouching system.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How do I use Executive Brain-Span Audit (MCI) correctly?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Always refer to the product instructions included with Executive Brain-Span Audit (MCI). In general, ensure peristomal skin is clean and dry before application, measure your stoma accurately, and change your pouching system every 1–3 days or when leakage is suspected. If you experience peristomal skin irritation, soreness, or persistent leakage, contact a WOC nurse or EMIS+ team for advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Executive Brain-Span Audit (MCI) in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Executive Brain-Span Audit (MCI) is available from EMIS+ at emis.asia — Singapore's trusted nurse-led stoma supply store. We stock a comprehensive range of ostomy products with fast island-wide delivery. Bulk orders for home care and nursing facilities are welcome. Contact us at emis.asia\/pages\/contact.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526346440782,"sku":null,"price":179.0,"currency_code":"SGD","in_stock":true}]}],"url":"https:\/\/www.emis.asia\/zh\/collections\/longevity-services.oembed","provider":"EMIS+","version":"1.0","type":"link"}